1
|
Hisatome I, Hamada T, Mizuta E, Ohtahara A, Kuwabara M, Ogino K, Ninomiya H, Sato Y, Nakayama T, Yamanaka H. Comparison of Recommendations Made by Committee Members with and without Financial Conflict of Interest on Japanese Guideline of Treatment of Hyperuricemia and Gout, Third Edition. JMA J 2023; 6:523-526. [PMID: 37941684 PMCID: PMC10628237 DOI: 10.31662/jmaj.2023-0067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2023] [Accepted: 07/26/2023] [Indexed: 11/10/2023] Open
Abstract
Clinical practice guidelines (CPGs) consist of clinical questions (CQs) and corresponding recommendations. Considering the estimation of body of evidence, patients' opinions, and medical economics, recommendations can vary depending on the votes of the committee members of CPGs. Taking this into consideration, concerns have already been raised on how financial conflict of interest (COI) potentially influences recommendations. In this study, we developed the third edition of guideline for the management of hyperuricemia and gout. This CPG was composed of seven CQs and recommendations. The direction and strength of the recommendations were determined by votes. There are three CQs. Individual questions asked whether uric acid-lowering-agents (ULAs) could be applied to hyperuricemic patients with chronic kidney disease (CKD) (CQ A), hypertension (CQ B), or heart failure (CQ C) to prevent organ damage. We examined whether the absence (18 members) or presence (8 members) of COIs of committee members could influence the votes. In total, 26 committee members with and without COI have equally determined the direction and strength of recommendations. In CQ A, members without financial COIs and those with financial COI selected conditional recommendation for the use of ULAs in patients with CKD (without COI, 17/18; with COI, 7/8). In CQ B, members without financial COIs and those with financial COI selected conditional recommendation against the use of ULAs in hypertensive patients (without COI, 14/18; with COI, 5/8). In CQ C, members without financial COIs and those with financial COIs have selected conditional recommendation against the use of ULAs in patients suffering from heart failure (without COI, 15/18; with COI, 4/8). We found that members with financial COIs have determined their recommendations in the same direction and strength as those without financial COIs.
Collapse
Affiliation(s)
- Ichiro Hisatome
- Department of Cardiology, National Hospital Organization, Yonago Medical Center, Yonago, Japan
| | - Toshihiro Hamada
- Department of Community-based Family Medicine, Tottori University Faculty of Medicine, Yonago, Japan
| | - Einosuke Mizuta
- Department of Cardiology, Sanin Rosai Hospital, Yonago, Japan
| | - Akira Ohtahara
- Department of Cardiology, Sanin Rosai Hospital, Yonago, Japan
| | | | - Kazuhide Ogino
- Department of Cardiology, Japanese Red Cross Tottori Hospital, Tottori, Japan
| | - Haruaki Ninomiya
- Department of Biological Regulation, Tottori University Faculty of Medicine, Yonago, Japan
| | - Yasuto Sato
- Graduate School of Public Health, Shizuoka Graduate University of Public Health, Shizuoka, Japan
| | - Takeo Nakayama
- Department of Health Informatics, Graduate School of Medicine & School of Public Health, Kyoto University, Kyoto, Japan
| | | |
Collapse
|
2
|
Notsu T, Kurata Y, Ninomiya H, Taufiq F, Komatsu K, Miake J, Sawano T, Tsuneto M, Shirayoshi Y, Hisatome I. Inhibition of the uric acid efflux transporter ABCG2 enhances stimulating effect of soluble uric acid on IL-1β production in murine macrophage-like J774.1 cells. Hypertens Res 2023; 46:2368-2377. [PMID: 37592041 DOI: 10.1038/s41440-023-01391-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2023] [Revised: 06/12/2023] [Accepted: 07/08/2023] [Indexed: 08/19/2023]
Abstract
Soluble uric acid (UA) absorbed by cells through UA transporters (UATs) accumulates intracellularly, activates the NLRP3 inflammasome and thereby increases IL-1β secretion. ABCG2 transporter excludes intracellular UA. However, it remains unknown whether ABCG2 inhibition leads to intracellular accumulation of UA and increases IL-1β production. In this study, we examined whether genetic and pharmacological inhibition of ABCG2 could increase IL-1β production in mouse macrophage-like J774.1 cells especially under hyperuricemic conditions. We determined mRNA and protein levels of pro-IL-1β, mature IL-1β, caspase-1 and several UATs in culture supernatants and lysates of J774.1 cells with or without soluble UA pretreatment. Knockdown experiments using an shRNA against ABCG2 and pharmacological experiments with an ABCG2 inhibitor were conducted. Extracellularly applied soluble UA increased protein levels of pro-IL-1β, mature IL-1β and caspase-1 in the culture supernatant from lipopolysaccharide (LPS)-primed and monosodium urate crystal (MSU)-stimulated J774.1 cells. J774.1 cells expressed UATs of ABCG2, GLUT9 and MRP4, and shRNA knockdown of ABCG2 increased protein levels of pro-IL-1β and mature IL-1β in the culture supernatant. Soluble UA increased mRNA and protein levels of ABCG2 in J774.1 cells without either LPS or MSU treatment. An ABCG2 inhibitor, febuxostat, but not a urate reabsorption inhibitor, dotinurad, enhanced IL-1β production in cells pretreated with soluble UA. In conclusion, genetic and pharmacological inhibition of ABCG2 enhanced IL-1β production especially under hyperuricemic conditions by increasing intracellularly accumulated soluble UA that activates the NLRP3 inflammasome and pro-IL-1β transcription in macrophage-like J774.1 cells.
Collapse
Affiliation(s)
- Tomomi Notsu
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University, Yonago, Japan
| | - Yasutaka Kurata
- Department of Physiology II, Kanazawa Medical University, Uchinada, 920-0293, Japan.
| | - Haruaki Ninomiya
- Department of Biological Regulation, Tottori University Faculty of Medicine, Yonago, Japan
| | - Fikri Taufiq
- Department of Cardiology, Faculty of Medicine, Brawijaya University, Kota Malang, Jawa Timur, Indonesia
| | - Koji Komatsu
- Department of Psychiatry disease, Tottori University, Yonago, Japan
| | - Junichiro Miake
- Division of Pharmacology, Department of Pathophysiological and Therapeutic Science, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Tatsuya Sawano
- Division of Pharmacology, Department of Pathophysiological and Therapeutic Science, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Motokazu Tsuneto
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University, Yonago, Japan
| | - Yasuaki Shirayoshi
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University, Yonago, Japan
| | - Ichiro Hisatome
- Department of Cardiology, National Hospital Organization Yonago Medical Center, Yonago, Japan
| |
Collapse
|
3
|
Miake J, Hisatome I, Tomita K, Isoyama T, Sugihara S, Kuwabara M, Ogino K, Ninomiya H. Impact of Hyper- and Hypo-Uricemia on Kidney Function. Biomedicines 2023; 11:biomedicines11051258. [PMID: 37238929 DOI: 10.3390/biomedicines11051258] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2023] [Revised: 04/18/2023] [Accepted: 04/19/2023] [Indexed: 05/28/2023] Open
Abstract
Uric acid (UA) forms monosodium urate (MSU) crystals to exert proinflammatory actions, thus causing gout arthritis, urolithiasis, kidney disease, and cardiovascular disease. UA is also one of the most potent antioxidants that suppresses oxidative stress. Hyper andhypouricemia are caused by genetic mutations or polymorphism. Hyperuricemia increases urinary UA concentration and is frequently associated with urolithiasis, which is augmented by low urinary pH. Renal hypouricemia (RHU) is associated with renal stones by increased level of urinary UA, which correlates with the impaired tubular reabsorption of UA. Hyperuricemia causes gout nephropathy, characterized by renal interstitium and tubular damage because MSU precipitates in the tubules. RHU is also frequently associated with tubular damage with elevated urinary beta2-microglobulin due to increased urinary UA concentration, which is related to impaired tubular UA reabsorption through URAT1. Hyperuricemia could induce renal arteriopathy and reduce renal blood flow, while increasing urinary albumin excretion, which is correlated with plasma xanthine oxidoreductase (XOR) activity. RHU is associated with exercise-induced kidney injury, since low levels of SUA could induce the vasoconstriction of the kidney and the enhanced urinary UA excretion could form intratubular precipitation. A U-shaped association of SUA with organ damage is observed in patients with kidney diseases related to impaired endothelial function. Under hyperuricemia, intracellular UA, MSU crystals, and XOR could reduce NO and activate several proinflammatory signals, impairing endothelial functions. Under hypouricemia, the genetic and pharmacological depletion of UA could impair the NO-dependent and independent endothelial functions, suggesting that RHU and secondary hypouricemia might be a risk factor for the loss of kidney functions. In order to protect kidney functions in hyperuricemic patients, the use of urate lowering agents could be recommended to target SUA below 6 mg/dL. In order to protect the kidney functions in RHU patients, hydration and urinary alkalization may be recommended, and in some cases an XOR inhibitor might be recommended in order to reduce oxidative stress.
Collapse
Affiliation(s)
- Junichiro Miake
- Division of Pharmacology, Department of Pathophysiological and Therapeutic Science, Tottori University Faculty of Medicine, Tottori 683-8503, Japan
| | - Ichiro Hisatome
- Department of Cardiology, Yonago Medical Center, Tottori 683-0006, Japan
| | - Katsuyuki Tomita
- Department of Respiratory Disease, Yonago Medical Center, Tottori 683-0006, Japan
| | - Tadahiro Isoyama
- Department of Urology, Yonago Medical Center, Tottori 683-0006, Japan
| | - Shinobu Sugihara
- Health Service Center, Shimane University, Matsue 690-0823, Japan
| | - Masanari Kuwabara
- Intensive Care Unit and Department of Cardiology, Toranomon Hospital, Tokyo 105-8470, Japan
| | - Kazuhide Ogino
- Department of Cardiology, Tottori Red Cross Hospital, Tottori 680-0017, Japan
| | - Haruaki Ninomiya
- Department of Biological Regulation, Tottori University Faculty of Medicine, Tottori 683-8503, Japan
| |
Collapse
|
4
|
Morita M, Suyama Y, Notsu T, Fukuoka K, Ikuta K, Kanayama H, Umeda R, Teraoka S, Minato H, Ninomiya H, Tsuneto M, Shirayoshi Y, Hisatome I, Yagi S. Effects of Conditioned Medium of Adipose-Derived Stem Cells Exposed to Platelet-Rich Plasma on the Expression of Endothelial Nitric Oxide Synthase and Angiogenesis by Endothelial Cells. Ann Plast Surg 2023; 90:171-179. [PMID: 36688861 PMCID: PMC9869946 DOI: 10.1097/sap.0000000000003368] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2022] [Accepted: 10/26/2022] [Indexed: 01/24/2023]
Abstract
ABSTRACT Platelet-rich plasma (PRP) and adipose-derived stem cells (ADSCs) are known to secrete angiogenic factors that contribute to the treatment of intractable ulcers. The combination of PRP and ADSCs may enhance their angiogenic effects. However, it remains unclear whether treatment of ADSCs with PRP influences angiogenesis. We studied whether the conditioned medium from PRP-treated ADSCs under hypoxic conditions exerts angiogenic effects. Although PRP stimulated the proliferation of ADSCs obtained from rats, it decreased the mRNA levels of vascular endothelial growth factor, hepatocyte growth factor, and TGF-β1, but not of basic fibroblast growth factor, under hypoxia. The conditioned medium of PRP-treated ADSCs inhibited endothelial nitric oxide synthase phosphorylation, decreased NO production, and suppressed tube formation in human umbilical vein endothelial cells. Transplantation of ADSCs alone increased both blood flow and capillary density of the ischemic limb; however, its combination with PRP did not further improve blood flow or capillary density. This suggests that both conditioned medium of ADSCs treated with PRP and combination of PRP with ADSCs transplantation may attenuate the phosphorylation of endothelial nitric oxide synthase and angiogenesis.
Collapse
Affiliation(s)
- Maki Morita
- From the Departments of Plastic and Reconstructive Surgery
| | - Yoshiko Suyama
- From the Departments of Plastic and Reconstructive Surgery
| | | | - Kohei Fukuoka
- From the Departments of Plastic and Reconstructive Surgery
| | - Kento Ikuta
- From the Departments of Plastic and Reconstructive Surgery
| | | | | | | | | | | | | | | | - Ichiro Hisatome
- Genomic Medicine and Regenerative Therapy
- Department of Cardiology, Yonago Medical Center, Yonago, Japan
| | - Shunjiro Yagi
- From the Departments of Plastic and Reconstructive Surgery
| |
Collapse
|
5
|
Adachi M, Watanabe M, Kurata Y, Inoue Y, Notsu T, Yamamoto K, Horie H, Tanno S, Morita M, Miake J, Hamada T, Kuwabara M, Nakasone N, Ninomiya H, Tsuneto M, Shirayoshi Y, Yoshida A, Nishimura M, Yamamoto K, Hisatome I. CORRIGENDUM: β-Adrenergic Blocker, Carvedilol, Abolishes Ameliorating Actions of Adipose-Derived Stem Cell Sheets on Cardiac Dysfunction and Remodeling After Myocardial Infarction. Circ J 2023; 87:1622. [PMID: 37743528 DOI: 10.1253/circj.cj-66-0217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 09/26/2023]
|
6
|
Miyazaki S, Hamada T, Isoyama T, Okada S, Tomita K, Endo Y, Kuwabara M, Sugihara S, Ogino K, Ninomiya H, Ichida K, Yamamoto K, Takenaka A, Hisatome I. Characterization of Urate Metabolism and Complications of Patients with Renal Hypouricemia. Intern Med 2022. [PMID: 36418091 PMCID: PMC10372278 DOI: 10.2169/internalmedicine.0457-22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Background Both renal hypouricemia (RHU) and gout are associated with renal dysfunction and urolithiasis. The difference in renal complications associated with RHU and gout, however, has not been studied. We characterized the urate metabolism and complications of patients with RHU and compared them with patients with gout. Methods Eighteen patients with RHU who had a serum uric acid (SUA) level <2 mg/dL (10 men and 8 women), 44 patients with gout (44 men) and 16 normouricemic patients (4 men and 12 women) were included. The blood and urinary biochemical data were evaluated. A genetic analysis of uric acid transporter 1 (URAT1) was also conducted in 15 cases with RHU. Results The SUA level of RHU was 0.9±0.5/mg/dl, and the Uur/Ucr and Cur/Ccr were 0.56%±0.14% and 45.7%±18.0%, respectively. A genetic analysis of URAT1 in 15 RHU patients showed that 13 harbored a URAT1 gene mutation, whereas 2 harbored the wild-type gene. The SUA level was significantly lower in RHU patients (n=11) than in either gout patients (n=44) or normouricemic patients (n=16). This reduction was accompanied by the elevation of Cua/Ccr. Urinary beta 2-microglobulin levels were higher in RHU patients than in gout or normouricemia patients. Cua/Ccr correlated with normalized urinary beta 2-microglobulin levels. The prevalence of urolithiasis was 18.2% in RHU cases and 6.8% in gout cases. A homozygous URAT1 mutation was associated with urolithiasis. Conclusion Besides urolithiasis, RHU can be associated with tubular dysfunction, such as elevated urinary beta 2-microglobulin levels.
Collapse
Affiliation(s)
| | - Toshihiro Hamada
- Department of Community-Based Family Medicine, Faculty of Medicine, Tottori University, Japan
| | | | | | | | - Yusuke Endo
- Advanced Medicine, Innovation and Clinical Research Center, Tottori University Hospital, Japan
| | | | | | - Kazuhide Ogino
- Department of Cardiology, Tottori Red Cross Hospital, Japan
| | - Haruaki Ninomiya
- Department of Biological Regulation, Faculty of Medicine, Tottori University, Japan
| | - Kimiyoshi Ichida
- Department of Pathophysiology, Tokyo University of Pharmacy and Life Sciences, Japan
| | - Kazuhiro Yamamoto
- Division of Cardiovascular Medicine, Department of Molecular Medicine and Therapeutics, Faculty of Medicine, Tottori University, Japan
| | | | - Ichiro Hisatome
- Department of Cardiovascular Medicine, Yonago Medical Center, Japan
| |
Collapse
|
7
|
Li P, Kurata Y, Taufiq F, Kuwabara M, Ninomiya H, Higaki K, Tsuneto M, Shirayoshi Y, Lanaspa MA, Hisatome I. Kv1.5 channel mediates monosodium urate-induced activation of NLRP3 inflammasome in macrophages and arrhythmogenic effects of urate on cardiomyocytes. Mol Biol Rep 2022; 49:5939-5952. [PMID: 35368226 PMCID: PMC9270276 DOI: 10.1007/s11033-022-07378-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2022] [Accepted: 03/15/2022] [Indexed: 11/10/2022]
Abstract
BACKGROUND Gout is usually found in patients with atrial fibrillation (AF). K+ efflux is a common trigger of NLRP3 inflammasome activation which is involved in the pathogenesis of AF. We investigated the role of the K+ channel Kv1.5 in monosodium urate crystal (MSU)-induced activation of the NLRP3 inflammasome and electrical remodeling in mouse and human macrophages J774.1 and THP-1, and mouse atrial myocytes HL-1. METHODS AND RESULTS Macrophages, primed with lipopolysaccharide (LPS), were stimulated by MSU. HL-1 cells were incubated with the conditioned medium (CM) from MSU-stimulated macrophages. Western blot, ELISA and patch clamp were used. MSU induced caspase-1 expression in LPS-primed J774.1 cells and IL-1β secretion, suggesting NLRP3 inflammasome activation. A selective Kv1.5 inhibitor, diphenyl phosphine oxide-1 (DPO-1), and siRNAs against Kv1.5 suppressed the levels of caspase-1 and IL-1β. MSU reduced intracellular K+ concentration which was prevented by DPO-1 and siRNAs against Kv1.5. MSU increased expression of Hsp70, and Kv1.5 on the plasma membrane. siRNAs against Hsp70 were suppressed but heat shock increased the expression of Hsp70, caspase-1, IL-1β, and Kv1.5 in MSU-stimulated J774.1 cells. The CM from MSU-stimulated macrophages enhanced the expression of caspase-1, IL-1β and Kv1.5 with increased Kv1.5-mediated currents that shortened action potential duration in HL-1 cells. These responses were abolished by DPO-1 and a siRNA against Kv1.5. CONCLUSIONS Kv1.5 regulates MSU-induced activation of NLRP3 inflammasome in macrophages. MSUrelated activation of NLRP3 inflammasome and electrical remodeling in HL-1 cells are via macrophages. Kv1.5 may have therapeutic value for diseases related to gout-induced activation of the NLRP3 inflammsome, including AF.
Collapse
Affiliation(s)
- Peili Li
- Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University, 36-1, Nishimachi, Yonago, Tottori, 683-8504, Japan.
| | - Yasutaka Kurata
- Department of Physiology II, Kanazawa Medical University, Kahoku, Ishikawa, 920-0293, Japan
| | - Fikri Taufiq
- Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University, 36-1, Nishimachi, Yonago, Tottori, 683-8504, Japan
| | - Masanari Kuwabara
- Intensive Care Unit and Department of Cardiology, Toranomon Hospital, Tokyo, 105-8470, Japan
| | - Haruaki Ninomiya
- Department of Biological Regulation, Tottori University, Yonago, 683-8504, Japan
| | - Katsumi Higaki
- Research Center for Bioscience and Technology, Tottori University, Yonago, 683-8504, Japan
| | - Motokazu Tsuneto
- Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University, 36-1, Nishimachi, Yonago, Tottori, 683-8504, Japan
| | - Yasuaki Shirayoshi
- Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University, 36-1, Nishimachi, Yonago, Tottori, 683-8504, Japan
| | - Miguel A Lanaspa
- Division of Renal Diseases and Hypertension, School of Medicine, University of Colorado Denver, Aurora, CO, 80045, USA
| | - Ichiro Hisatome
- Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University, 36-1, Nishimachi, Yonago, Tottori, 683-8504, Japan
| |
Collapse
|
8
|
Hamada T, Hisatome I, Wakimizu T, Kato M, Gotou T, Koga A, Endo Y, Taniguchi SI, Yamamoto K, Ninomiya H, Tsuboi H, Yamaguchi M, Yamada N, Kano H, Asami Y. Lactobacillus gasseri PA-3 reduces serum uric acid levels in patients with marginal hyperuricemia. Nucleosides Nucleotides Nucleic Acids 2022; 41:361-369. [PMID: 35227163 DOI: 10.1080/15257770.2022.2039702] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/28/2021] [Revised: 01/22/2022] [Accepted: 02/04/2022] [Indexed: 06/14/2023]
Abstract
Several studies have reported that Lactobacillus gasseri PA-3 reduces the level of serum uric acid (SUA) in patients with hyperuricemia. However, it remains unknown how PA-3 affects uric acid metabolism. In the present study, we examined effects of PA-3-containing yoghurt on uric acid metabolism in patients with marginal hyperuricemia. Sixteen patients with SUA > 357 μmol/L (marginal hyperuricemia) were enrolled. PA-3-containing yoghurt was administered for 8 weeks. Uric acid metabolism was evaluated just before and 8 weeks after the administration and at 4 weeks after the administration ended (post-administration). SUA levels after the administration were significantly lower than that before the administration and remained low at post-administration. Urinary uric acid concentration (Uur) after the administration were significantly lower than that before the administration. However, post-administration Uur levels were comparable to those before the administration. Therefore, PA-3-containing yoghurt significantly reduced the levels of SUA and Uur in patients with marginal hyperuricemia.
Collapse
Affiliation(s)
- Toshihiro Hamada
- Faculty of Medicine, Department of Community-Based Family Medicine, Tottori University, Yonago, Japan
| | - Ichiro Hisatome
- Department of Cardiology, Yonago Medical Center, Yonago, Japan
| | - Takayuki Wakimizu
- Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Graduate School of Medical Science, Tottori University, Yonago, Japan
| | - Masahiko Kato
- Division of School of Health Science, Department of Pathobiological Science and Technology, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Tamotsu Gotou
- Department of Pediatric Emergency and Intensive Care Medicine, Department of Emergency and Intensive Care Medicine, Tottori Prefectural Central Hospital, Tottori, Japan
| | - Atsuro Koga
- Advanced Medicine & Translational Research Center, Organization for Research Initiative and Promotion, Tottori University, Yonago, Japan
| | - Yusuke Endo
- Advanced Medicine & Translational Research Center, Organization for Research Initiative and Promotion, Tottori University, Yonago, Japan
| | - Shin-Ichi Taniguchi
- Faculty of Medicine, Department of Community-Based Family Medicine, Tottori University, Yonago, Japan
| | - Kazuhiro Yamamoto
- Department of Cardiovascular Medicine, and Endocrinology and Metabolism, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Haruaki Ninomiya
- Department of Biological Regulation, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Hiroshi Tsuboi
- Food Microbiology and Function Research Laboratories, Meiji Co., Ltd, Tokyo, Japan
| | - Makoto Yamaguchi
- Food Microbiology and Function Research Laboratories, Meiji Co., Ltd, Tokyo, Japan
| | - Naruomi Yamada
- Food Microbiology and Function Research Laboratories, Meiji Co., Ltd, Tokyo, Japan
| | - Hiroshi Kano
- Food Microbiology and Function Research Laboratories, Meiji Co., Ltd, Tokyo, Japan
| | - Yukio Asami
- Food Microbiology and Function Research Laboratories, Meiji Co., Ltd, Tokyo, Japan
| |
Collapse
|
9
|
Utami SB, Endo R, Hamada T, Notsu T, Minato H, Komatsu K, Nakayama Y, Shirayoshi Y, Yamamoto K, Okada S, Ninomiya H, Otuki A, Hisatome I. Hsp70 promotes maturation of uromodulin mutants that cause familial juvenile hyperuricemic nephropathy and suppresses cellular damage. Clin Exp Nephrol 2022; 26:522-529. [PMID: 35212881 DOI: 10.1007/s10157-022-02196-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2021] [Accepted: 02/04/2022] [Indexed: 11/28/2022]
Abstract
BACKGROUND Familial juvenile hyperuricemic nephropathy (FJHN) is an autosomal dominant disorder caused by mutations in UMOD. Here we studied effects of genetic expression and pharmacological induction of Hsp70 on the UMOD mutants C112Y and C217G. METHODS We expressed wild type (WT), C112Y and C217G in HEK293 cells and studied their maturation and cellular damage using western blot and flow cytometry. RESULTS Expression of C112Y or C217G increased pro-apoptotic proteins, decreased anti-apoptotic proteins, and induced cellular apoptosis as examined by annexin V staining and flow cytometry. Overexpression of Hsp70 or administration of an Hsp70 inducer geranylgeranylacetone (GGA) promoted maturation of the mutant proteins, increased their secreted forms, normalized the levels of pro- and anti-apoptotic proteins and suppressed apoptosis. CONCLUSION These findings indicated that Hsp70 enhanced maturation of C112Y and C217G and reduced cellular apoptosis, suggesting that Hsp70 induction might be of a therapeutic value for treatment of FJHN.
Collapse
Affiliation(s)
- Sulistiyati Bayu Utami
- Department of Genetic Medicine and Regenerative Therapeutics, Faculty of Medicine, Tottori University, Yonago, Japan.,Department of Cardiology and Vascular Medicine, Diponegoro University, Semarang, Indonesia
| | - Ryo Endo
- Department of Anesthesiology, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Toshihiro Hamada
- Department of Community-Based Family Medicine, Faculty of Medicine, Tottori University, Yonago, Japan.
| | - Tomomi Notsu
- Department of Genetic Medicine and Regenerative Therapeutics, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Hiroyuki Minato
- Department of Anesthesiology, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Koji Komatsu
- Department of Psychiatry, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Yuji Nakayama
- Research Center for Bioscience and Technology, Tottori University, Yonago, Japan
| | - Yasuaki Shirayoshi
- Department of Genetic Medicine and Regenerative Therapeutics, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Kazuhiro Yamamoto
- Division of Cardiovascular Medicine, Department of Molecular Medicine and Therapeutics, Faculty of Medicine, Tottori University, Yonago, 683-8503, Japan
| | - Shinichi Okada
- Department of Pediatrics, Yonago Medical Center, Yonago, Japan
| | - Haruaki Ninomiya
- Department of Biological Regulation, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Akihiro Otuki
- Department of Anesthesiology, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Ichiro Hisatome
- Department of Genetic Medicine and Regenerative Therapeutics, Faculty of Medicine, Tottori University, Yonago, Japan.,Department of Cardiovascular Medicine, Yonago Medical Center, Yonago, Japan
| |
Collapse
|
10
|
Miyazaki S, Hamada T, Sugihara S, Mizuta E, Endo Y, Ohtahara A, Komatsu K, Kuwabara M, Fukuuchi T, Kaneko K, Ichida K, Ogino K, Ninomiya H, Yamamoto K, Nakamura T, Hisatome I. Xanthinuria Type 1 with a Novel Mutation in Xanthine Dehydrogenase and a Normal Endothelial Function. Intern Med 2022; 61:1383-1386. [PMID: 35491177 PMCID: PMC9152847 DOI: 10.2169/internalmedicine.7897-21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Whether or not extremely low levels of serum uric acid (SUA) in xanthinuria are associated with impairment of the endothelial function and exercise-induced acute kidney injury (EIAKI) is unclear. A 59-year-old woman without EIAKI or urolithiasis had undetectable levels of UA in serum and urine and elevated levels of hypoxanthine and xanthine in urine. A genetic analysis revealed homozygous mutations in the XDH gene [c.1585 C>T (p. Gln529*)]. Flow-mediated dilation was within the normal range. This is the first report of a case with extremely low levels of SUA, xanthinuria with novel mutations of xanthine dehydrogenase (XDH) and a normal endothelial function.
Collapse
Affiliation(s)
| | - Toshihiro Hamada
- Department of Community-Based Family Medicine, Tottori University, Faculty of Medicine, Japan
| | | | | | - Yusuke Endo
- Advanced Medicine, Innovation and Clinical Research Center, Tottori University Hospital, Japan
| | | | - Koji Komatsu
- Department of Psychiatry Disease, Tottori University, Japan
| | | | - Tomoko Fukuuchi
- Laboratory of Biomedical and Analytical Sciences, Faculty of Pharma-Science, Teikyo University, Japan
| | - Kiyoko Kaneko
- Faculty of Pharmaceutical Sciences, Teikyo Heisei University, Japan
| | - Kimiyoshi Ichida
- Department of Pathophysiology, Tokyo University of Pharmacy and Life Sciences, Japan
| | - Kazuhide Ogino
- Department of Cardiology, Japanese Red Cross Tottori Hospital, Japan
| | - Haruaki Ninomiya
- Department of Biological Regulation, Tottori University Faculty of Medicine, Japan
| | - Kazuhiro Yamamoto
- Division of Cardiovascular Medicine, Department of Molecular Medicine and Therapeutics, Faculty of Medicine, Tottori University, Japan
| | | | - Ichiro Hisatome
- Department of Cardiovascular Medicine, Yonago Medical Center, Japan
| |
Collapse
|
11
|
Horie H, Hisatome I, Kurata Y, Yamamoto Y, Notsu T, Adachi M, Li P, Kuwabara M, Sakaguchi T, Kinugasa Y, Miake J, Koba S, Tsuneto M, Shirayoshi Y, Ninomiya H, Ito S, Kitakaze M, Yamamoto K, Yoshikawa Y, Nishimura M. α1-Adrenergic receptor mediates adipose-derived stem cell sheet-induced protection against chronic heart failure after myocardial infarction in rats. Hypertens Res 2021; 45:283-291. [PMID: 34853408 DOI: 10.1038/s41440-021-00802-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2021] [Revised: 09/08/2021] [Accepted: 10/15/2021] [Indexed: 11/09/2022]
Abstract
Cell-based therapy using adipose-derived stem cells (ADSCs) has emerged as a novel therapeutic approach to treat heart failure after myocardial infarction (MI). The purpose of this study was to determine whether inhibition of α1-adrenergic receptors (α1-ARs) in ADSCs attenuates ADSC sheet-induced improvements in cardiac functions and inhibition of remodeling after MI. ADSCs were isolated from fat tissues of Lewis rats. In in vitro studies using cultured ADSCs, we determined the mRNA levels of vascular endothelial growth factor (VEGF)-A and α1-AR under normoxia or hypoxia and the effects of norepinephrine and an α1-blocker, doxazosin, on the mRNA levels of angiogenic factors. Hypoxia increased α1-AR and VEGF mRNA levels in ADSCs. Norepinephrine further increased VEGF mRNA expression under hypoxia; this effect was abolished by doxazosin. Tube formation of human umbilical vein endothelial cells was promoted by conditioned media of ADSCs treated with the α1 stimulant phenylephrine under hypoxia but not by those of ADSCs pretreated with phenylephrine plus doxazosin. In in vivo studies using rats with MI, transplanted ADSC sheets improved cardiac functions, facilitated neovascularization, and suppressed fibrosis after MI. These effects were abolished by doxazosin treatment. Pathway analysis from RNA sequencing data predicted significant upregulation of α1-AR mRNA expression in transplanted ADSC sheets and the involvement of α1-ARs in angiogenesis through VEGF. In conclusion, doxazosin abolished the beneficial effects of ADSC sheets on rat MI hearts as well as the enhancing effect of norepinephrine on VEGF expression in ADSCs, indicating that ADSC sheets promote angiogenesis and prevent cardiac dysfunction and remodeling after MI via their α1-ARs.
Collapse
Affiliation(s)
- Hiromu Horie
- Division of Cardiovascular Surgery, Department of Surgery, Tottori University Faculty of Medicine, Yonago, Japan
| | - Ichiro Hisatome
- Division of Regenerative Medicine and Therapeutics, Tottori University Graduate School of Medical Science, Yonago, Japan
| | - Yasutaka Kurata
- Department of Physiology II, Kanazawa Medical University, Uchinada, Japan.
| | - Yasutaka Yamamoto
- Division of Regenerative Medicine and Therapeutics, Tottori University Graduate School of Medical Science, Yonago, Japan
| | - Tomomi Notsu
- Division of Regenerative Medicine and Therapeutics, Tottori University Graduate School of Medical Science, Yonago, Japan
| | - Maaya Adachi
- Division of Regenerative Medicine and Therapeutics, Tottori University Graduate School of Medical Science, Yonago, Japan
| | - Peili Li
- Division of Regenerative Medicine and Therapeutics, Tottori University Graduate School of Medical Science, Yonago, Japan
| | - Masanari Kuwabara
- Intensive Care Unit and Department of Cardiology, Toranomon Hospital, Tokyo, Japan
| | - Takuki Sakaguchi
- Division of Medical Education, Department of Medical Education, Tottori University Faculty of Medicine, Yonago, Japan
| | - Yoshiharu Kinugasa
- Division of Cardiovascular Medicine, Department of Molecular Medicine and Therapeutics, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Junichiro Miake
- Department of Pharmacology, Tottori University Faculty of Medicine, Yonago, Japan
| | - Satoshi Koba
- Division of Integrative Physiology, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Motokazu Tsuneto
- Division of Regenerative Medicine and Therapeutics, Tottori University Graduate School of Medical Science, Yonago, Japan
| | - Yasuaki Shirayoshi
- Division of Regenerative Medicine and Therapeutics, Tottori University Graduate School of Medical Science, Yonago, Japan
| | - Haruaki Ninomiya
- Department of Biological Regulation, Tottori University Faculty of Medicine, Yonago, Japan
| | - Shin Ito
- Department of Clinical Research and Development, National Cerebral and Cardiovascular Center, Suita, Japan
| | | | - Kazuhiro Yamamoto
- Division of Cardiovascular Medicine, Department of Molecular Medicine and Therapeutics, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Yasushi Yoshikawa
- Division of Cardiovascular Surgery, Department of Surgery, Tottori University Faculty of Medicine, Yonago, Japan
| | - Motonobu Nishimura
- Division of Cardiovascular Surgery, Department of Surgery, Tottori University Faculty of Medicine, Yonago, Japan
| |
Collapse
|
12
|
Matsuura Y, Ninomiya H, Hashimoto K, Ichinose J, Nakao M, Okumura S, Nishio M, Mun M. P53.04 Local Therapies vs. Specific TKIs as the Initial Treatment for Oligo-Recurrent Lung Adenocarcinoma With Driver Mutations. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.553] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
13
|
Watanabe M, Horie H, Kurata Y, Inoue Y, Notsu T, Wakimizu T, Adachi M, Yamamoto K, Morikawa K, Kuwabara M, Sakaguchi T, Morisaki T, Miake J, Nishimura M, Tsuneto M, Shirayoshi Y, Ito S, Kitakaze M, Ninomiya H, Yamamoto K, Hisatome I. Esm1 and Stc1 as Angiogenic Factors Responsible for Protective Actions of Adipose-Derived Stem Cell Sheets on Chronic Heart Failure After Rat Myocardial Infarction. Circ J 2021; 85:657-666. [PMID: 33716265 DOI: 10.1253/circj.cj-20-0877] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND Although adipose-derived stem cell (ADSC) sheets improve the cardiac function after myocardial infarction (MI), underlying mechanisms remain to be elucidated. The aim of this study was to determine the fate of transplanted ADSC sheets and candidate angiogenic factors released from ADSCs for their cardiac protective actions.Methods and Results:MI was induced by ligation of the left anterior descending coronary artery. Sheets of transgenic (Tg)-ADSCs expressing green fluorescence protein (GFP) and luciferase or wild-type (WT)-ADSCs were transplanted 1 week after MI. Both WT- and Tg-ADSC sheets improved cardiac functions evaluated by echocardiography at 3 and 5 weeks after MI. Histological examination at 5 weeks after MI demonstrated that either sheet suppressed fibrosis and increased vasculogenesis. Luciferase signals from Tg-ADSC sheets were detected at 1 and 2 weeks, but not at 4 weeks, after transplantation. RNA sequencing of PKH (yellow-orange fluorescent dye with long aliphatic tails)-labeled Tg-ADSCs identified mRNAs of 4 molecules related to angiogenesis, including those of Esm1 and Stc1 that increased under hypoxia. Administration of Esm1 or Stc1 promoted tube formation by human umbilical vein endothelial cells. CONCLUSIONS ADSC sheets improved cardiac contractile functions after MI by suppressing cardiac fibrosis and enhancing neovascularization. Transplanted ADSCs existed for >2 weeks on MI hearts and produced the angiogenic factors Esm1 and Stc1, which may improve cardiac functions after MI.
Collapse
Affiliation(s)
- Mai Watanabe
- Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| | - Hiromu Horie
- Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| | | | - Yumiko Inoue
- Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| | - Tomomi Notsu
- Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| | - Takayuki Wakimizu
- Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| | - Maya Adachi
- Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| | - Kenshiro Yamamoto
- Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| | - Kumi Morikawa
- Biomaterials Research Group, Department of Life Science and Biotechnology, Health and Medical Research Institute, National Institute of Advanced Industrial Science and Technology
| | - Masanari Kuwabara
- Intensive Care Unit and Department of Cardiology, Toranomon Hospital
| | - Takuki Sakaguchi
- Division of Gastroenterology and Nephrology, Department of Multidisciplinary Internal Medicine, Tottori University Faculty of Medicine
| | - Takayuki Morisaki
- Division of Molecular Pathology/Department of Internal Medicine IMSUT Hospital, The Institute of Medical Science, The University of Tokyo
| | - Junichiro Miake
- Department of Pharmacology, Tottori University Faculty of Medicine
| | - Motonobu Nishimura
- Division of Cardiovascular Surgery, Department of Surgery, Tottori University Faculty of Medicine
| | - Motokazu Tsuneto
- Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| | - Yasuaki Shirayoshi
- Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| | - Shin Ito
- Department of Clinical Research and Development, National Cerebral and Cardiovascular Center
| | | | - Haruaki Ninomiya
- Department of Biological Regulation, Tottori University Faculty of Medicine
| | - Kazuhiro Yamamoto
- Division of Cardiovascular Medicine, Department of Molecular Medicine and Therapeutics, Tottori University Faculty of Medicine
| | - Ichiro Hisatome
- Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| |
Collapse
|
14
|
Hisatome I, Li P, Miake J, Taufiq F, Mahati E, Maharani N, Utami SB, Kuwabara M, Bahrudin U, Ninomiya H. Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease ― Japanese Guideline on the Management of Asymptomatic Hyperuricemia ―. Circ J 2021; 85:130-138. [DOI: 10.1253/circj.cj-20-0406] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Ichiro Hisatome
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science
| | - Peili Li
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science
| | - Junichiro Miake
- Department of Pharmacology, Tottori University Faculty of Medicine
| | - Fikri Taufiq
- Department of Physiology, Faculty of Medicine, Sultan Agung Islamic University
| | - Endang Mahati
- Department of Pharmacology and Therapy, Faculty of Medicine, Diponegoro University
| | - Nani Maharani
- Department of Pharmacology and Therapy, Faculty of Medicine, Diponegoro University
| | - Sulistiyati Bayu Utami
- Department of Cardiology and Vascular Medicine, Faculty of Medicine, Diponegoro University
| | - Masanari Kuwabara
- Intensive Care Unit and Department of Cardiology, Toranomon Hospital
| | - Udin Bahrudin
- Department of Cardiology and Vascular Medicine, Faculty of Medicine, Diponegoro University
| | - Haruaki Ninomiya
- Department of Biological Regulation, Tottori University Faculty of Medicine
| |
Collapse
|
15
|
Otani N, Kurata Y, Maharani N, Kuwabara M, Ikeda N, Notsu T, Li P, Miake J, Yoshida A, Sakaguchi H, Higaki K, Nakasone N, Tsuneto M, Shirayoshi Y, Ouchi M, Ninomiya H, Yamamoto K, Anzai N, Hisatome I. Evidence for Urate Uptake Through Monocarboxylate Transporter 9 Expressed in Mammalian Cells and Its Enhancement by Heat Shock. Circ Rep 2020; 2:425-432. [PMID: 33693264 PMCID: PMC7819574 DOI: 10.1253/circrep.cr-20-0016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
Background: Monocarboxylate transporter 9 (MCT9), an orphan transporter member of the solute carrier family 16 (SLC16), possibly reabsorbs uric acid in the renal tubule and has been suggested by genome-wide association studies to be involved in the development of hyperuricemia and gout. In this study we investigated the mechanisms regulating the expression of human (h) MCT9, its degradation, and physiological functions. Methods and Results: hMCT9-FLAG was stably expressed in HEK293 cells and its degradation, intracellular localization, and urate uptake activities were assessed by pulse-chase analysis, immunofluorescence, and [14C]-urate uptake experiments, respectively. hMCT9-FLAG was localized on the plasma membrane as well as in the endoplasmic reticulum and Golgi apparatus. The proteasome inhibitors MG132 and lactacystine increased levels of hMCT9-FLAG protein expression with enhanced ubiquitination, prolonged their half-life, and decreased [14C]-urate uptake. [14C]-urate uptake was increased by both heat shock (HS) and the HS protein inducer geranylgeranylacetone (GGA). Both HS and GGA restored the [14C]-urate uptake impaired by MG132. Conclusions: hMCT9 does transport urate and is degraded by a proteasome, inhibition of which reduces hMCT9 expression on the cell membrane and urate uptake. HS enhanced urate uptake through hMCT9.
Collapse
Affiliation(s)
- Naoyuki Otani
- Department of Clinical Pharmacology and Therapeutics, Oita University Faculty of Medicine Oita Japan
| | - Yasutaka Kurata
- Department of Physiology II, Kanazawa Medical University Ishikawa Japan
| | - Nani Maharani
- Department of Pharmacology and Therapy, Faculty of Medicine Diponegoro University Semarang Indonesia
| | - Masanari Kuwabara
- Intensive Care Unit and Department of Cardiology, Toranomon Hospital Tokyo Japan
| | - Nobuhito Ikeda
- Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science Tottori Japan
| | - Tomomi Notsu
- Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science Tottori Japan
| | - Peili Li
- Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science Tottori Japan
| | - Junichiro Miake
- Department of Pharmacology, Tottori University Faculty of Medicine Tottori Japan
| | - Akio Yoshida
- Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science Tottori Japan
| | - Hiromi Sakaguchi
- Department of Radiology, Tottori University Faculty of Medicine Tottori Japan
| | - Katsumi Higaki
- Division of Functional Genomics, Tottori University Research Center for Bioscience and Technology Tottori Japan
| | - Naoe Nakasone
- Department of Biological Regulation, Tottori University Faculty of Medicine Tottori Japan
| | - Motokazu Tsuneto
- Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science Tottori Japan
| | - Yasuaki Shirayoshi
- Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science Tottori Japan
| | - Motoshi Ouchi
- Department of Pharmacology and Toxicology, Dokkyo Medical University School of Medicine Tochigi Japan
| | - Haruaki Ninomiya
- Department of Biological Regulation, Tottori University Faculty of Medicine Tottori Japan
| | - Kazuhiro Yamamoto
- Division of Cardiovascular Medicine, Department of Molecular Medicine and Therapeutics, Tottori University Faculty of Medicine Tottori Japan
| | - Naohiko Anzai
- Department of Pharmacology, Chiba University Graduate School of Medicine Chiba Japan
| | - Ichiro Hisatome
- Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science Tottori Japan
| |
Collapse
|
16
|
Kusunoki-Ii M, Kohama H, Kato K, Nomura Y, Nagashima K, Ninomiya H, Kato M, Kato S. Ultrastructure of spinal anterior horn cells in human Niemann-Pick type C (NPC) patient and mouse model of NPC with retroposon insertion in NPC1 genes. Pathol Int 2020; 70:422-432. [PMID: 32342600 DOI: 10.1111/pin.12934] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2019] [Revised: 03/13/2020] [Accepted: 03/26/2020] [Indexed: 11/29/2022]
Abstract
Niemann-Pick disease type C (NPC) is a neurovisceral lipid-storage disease. Although NPC patients show lipid storage in anterior horn cells of the spinal cord, little information is available regarding the electron microscopic analyses of the morphologies of intra-endosomal lipid like-materials in the anterior horn cells of NPC patients. In this study, we elucidated the intra-endosomal ultrastructures in spinal anterior horn cells in an NPC patient, as well as in mutant BALB/c NPC1-/- mice with a retroposon insertion in the NPC1 gene. These morphologies were classified into four types: vesicle, multiple concentric sphere (MCS), membrane, and rose flower. The percentages of the composition in the NPC patient and NPC1-/- mice were: vesicle (55.5% and 14.9%), MCS (15.7% and 3.4%), membrane (23.6% and 57.1%), and rose flower (5.2% and 24.6%), respectively. Formation of the intra-endosomal structures could proceed as follows: (i) a vesicle or MCS buds off the endosome into the lumen; (ii) when a vesicle breaks down, a membrane is formed; and (iii) after an MCS breaks down, a rose flower structure is formed. Our new finding in this study is that ultrastructural morphology is the same between the NPC patient and NPC1-/- mice, although there are differences in the composition.
Collapse
Affiliation(s)
- Masahiro Kusunoki-Ii
- Division of Neuropathology, Faculty of Medicine, Tottori University, Tottori, Japan
| | - Hiroshi Kohama
- Division of Neuropathology, Faculty of Medicine, Tottori University, Tottori, Japan
| | - Kiyota Kato
- School of Medicine, Hiroshima University, Hiroshima, Japan
| | - Yoshiko Nomura
- Yoshiko Nomura Neurological Clinic for Children, Tokyo, Japan
| | - Kazuo Nagashima
- Division of Pathology, Sapporo Higashi Tokushukai Hospital, Hokkaido, Japan
| | - Haruaki Ninomiya
- Department of Biological Regulation, Faculty of Medicine, Tottori University, Tottori, Japan
| | - Masako Kato
- Division of Pathology, Faculty of Medicine, Tottori University, Tottori, Japan
| | - Shinsuke Kato
- Division of Neuropathology, Faculty of Medicine, Tottori University, Tottori, Japan
| |
Collapse
|
17
|
Minato H, Hisatome I, Kurata Y, Notsu T, Nakasone N, Ninomiya H, Hamada T, Tomomori T, Okamura A, Miake J, Tsuneto M, Shirayoshi Y, Endo R, Otsuki A, Okada F, Inagaki Y. Pretreatment with cilnidipine attenuates hypoxia/reoxygenation injury in HL-1 cardiomyocytes through enhanced NO production and action potential shortening. Hypertens Res 2020; 43:380-388. [PMID: 31942044 DOI: 10.1038/s41440-019-0391-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2019] [Revised: 11/15/2019] [Accepted: 12/03/2019] [Indexed: 11/09/2022]
Abstract
Myocardial ischemia/reperfusion injury worsens in the absence of nitric oxide synthase (NOS). Cilnidipine, a Ca2+ channel blocker, has been reported to activate endothelial NOS (eNOS) and increases nitric oxide (NO) in vascular endothelial cells. We examined whether pretreatment with cilnidipine could attenuate cardiac cell deaths including apoptosis caused by hypoxia/reoxygenation (H/R) injury. HL-1 mouse atrial myocytes as well as H9c2 rat ventricular cells were exposed to H/R, and cell viability was evaluated by an autoanalyzer and flow cytometry; eNOS expression, NO production, and electrophysiological properties were also evaluated by western blotting, colorimetry, and patch clamping, respectively, in the absence and presence of cilnidipine. Cilnidipine enhanced phosphorylation of eNOS and NO production in a concentration-dependent manner, which was abolished by siRNAs against eNOS or an Hsp90 inhibitor, geldanamycin. Pretreatment with cilnidipine attenuated cell deaths including apoptosis during H/R; this effect was reproduced by an NO donor and a xanthine oxidase inhibitor. The NOS inhibitor L-NAME abolished the protective action of cilnidipine. Pretreatment with cilnidipine also attenuated H9c2 cell death during H/R. Additional cilnidipine treatment during H/R did not significantly enhance its protective action. There was no significant difference in the protective effect of cilnidipine under normal and high Ca2+ conditions. Action potential duration (APD) of HL-1 cells was shortened by cilnidipine, with this shortening augmented after H/R. L-NAME attenuated the APD shortening caused by cilnidipine. These findings indicate that cilnidipine enhances NO production, shortens APD in part by L-type Ca2+ channel block, and thereby prevents HL-1 cell deaths during H/R.
Collapse
Affiliation(s)
- Hiroyuki Minato
- Department of Anesthesiology and Critical Care Medicine, Tottori University Faculty of Medicine, 86 Nishi-cho, Yonago, 683-8503, Japan
| | - Ichiro Hisatome
- Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science, 86 Nishi-cho, Yonago, 683-8503, Japan
| | - Yasutaka Kurata
- Department of Physiology II, Kanazawa Medical University, Ishikawa, 920-0268, Japan.
| | - Tomomi Notsu
- Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science, 86 Nishi-cho, Yonago, 683-8503, Japan
| | - Naoe Nakasone
- Department of Biological Regulation, Tottori University, Yonago, 683-8503, Japan
| | - Haruaki Ninomiya
- Department of Biological Regulation, Tottori University, Yonago, 683-8503, Japan
| | - Toshihiro Hamada
- Department of Community-Based Family Medicine, Tottori University Faculty of Medicine, Yonago, 683-8503, Japan
| | - Takuya Tomomori
- Department of Molecular Medicine and Therapeutics, Tottori University Faculty of Medicine, Yonago, 683-8503, Japan
| | - Akihiro Okamura
- Department of Molecular Medicine and Therapeutics, Tottori University Faculty of Medicine, Yonago, 683-8503, Japan
| | - Junichiro Miake
- Department of Pharmacology, Tottori University Faculty of Medicine, Yonago, 683-8503, Japan
| | - Motokazu Tsuneto
- Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science, 86 Nishi-cho, Yonago, 683-8503, Japan
| | - Yasuaki Shirayoshi
- Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science, 86 Nishi-cho, Yonago, 683-8503, Japan
| | - Ryo Endo
- Department of Anesthesiology and Critical Care Medicine, Tottori University Faculty of Medicine, 86 Nishi-cho, Yonago, 683-8503, Japan
| | - Akihiro Otsuki
- Department of Anesthesiology and Critical Care Medicine, Tottori University Faculty of Medicine, 86 Nishi-cho, Yonago, 683-8503, Japan
| | - Futoshi Okada
- Division of Pathological Biochemistry, Tottori University Faculty of Medicine, Yonago, 683-8503, Japan
| | - Yoshimi Inagaki
- Department of Anesthesiology and Critical Care Medicine, Tottori University Faculty of Medicine, 86 Nishi-cho, Yonago, 683-8503, Japan
| |
Collapse
|
18
|
Adachi M, Watanabe M, Kurata Y, Inoue Y, Notsu T, Yamamoto K, Horie H, Tanno S, Morita M, Miake J, Hamada T, Kuwabara M, Nakasone N, Ninomiya H, Tsuneto M, Shirayoshi Y, Yoshida A, Nishimura M, Yamamoto K, Hisatome I. β-Adrenergic Blocker, Carvedilol, Abolishes Ameliorating Actions of Adipose-Derived Stem Cell Sheets on Cardiac Dysfunction and Remodeling After Myocardial Infarction. Circ J 2019; 83:2282-2291. [PMID: 31527337 DOI: 10.1253/circj.cj-19-0261] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND Treatment of myocardial infarction (MI) includes inhibition of the sympathetic nervous system (SNS). Cell-based therapy using adipose-derived stem cells (ASCs) has emerged as a novel therapeutic approach to treat heart failure in MI. The purpose of this study was to determine whether a combination of ASC transplantation and SNS inhibition synergistically improves cardiac functions after MI.Methods and Results:ASCs were isolated from fat tissues of Lewis rats. In in vitro studies using cultured ASC cells, mRNA levels of angiogenic factors under normoxia or hypoxia, and the effects of norepinephrine and a β-blocker, carvedilol, on the mRNA levels were determined. Hypoxia increased vascular endothelial growth factor (VEGF) mRNA in ASCs. Norepinephrine further increased VEGF mRNA; this effect was unaffected by carvedilol. VEGF promoted VEGF receptor phosphorylation and tube formation of human umbilical vein endothelial cells, which were inhibited by carvedilol. In in vivo studies using a rat MI model, transplanted ASC sheets improved contractile functions of MI hearts; they also facilitated neovascularization and suppressed fibrosis after MI. These beneficial effects of ASC sheets were abolished by carvedilol. The effects of ASC sheets and carvedilol on MI heart functions were confirmed by Langendorff perfusion experiments using isolated hearts. CONCLUSIONS ASC sheets prevented cardiac dysfunctions and remodeling after MI in a rat model via VEGF secretion. Inhibition of VEGF effects by carvedilol abolished their beneficial effects.
Collapse
Affiliation(s)
- Maya Adachi
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| | - Mai Watanabe
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| | - Yasutaka Kurata
- Department of Physiology II, Kanazawa Medical University Faculty of Medicine
| | - Yumiko Inoue
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| | - Tomomi Notsu
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| | - Kenshiro Yamamoto
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| | - Hiromu Horie
- Department of Cardiovascular Surgery, Tottori University Faculty of Medicine
| | - Shogo Tanno
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| | - Maki Morita
- Department of Plastic and Reconstructive Surgery, Tottori University Faculty of Medicine
| | - Junichiro Miake
- Division of Cardiovascular Medicine, Department of Molecular Medicine and Therapeutics, Tottori University Faculty of Medicine
| | - Toshihiro Hamada
- Department of Community-Based Family Medicine, Tottori University Faculty of Medicine
| | | | - Naoe Nakasone
- Department of Biological Regulation, Tottori University
| | | | - Motokazu Tsuneto
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| | - Yasuaki Shirayoshi
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| | - Akio Yoshida
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| | - Motonobu Nishimura
- Department of Cardiovascular Surgery, Tottori University Faculty of Medicine
| | - Kazuhiro Yamamoto
- Division of Cardiovascular Medicine, Department of Molecular Medicine and Therapeutics, Tottori University Faculty of Medicine
| | - Ichiro Hisatome
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| |
Collapse
|
19
|
Ichinose J, Ninomiya H, Nagano H, Matsuura Y, Nakao M, Okumura S, Mun M. MA18.03 Distinction Between Primary Lung Cancer and Pulmonary Metastasis of Esophageal Cancer Using the Nanostring nCounter System. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.648] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
20
|
Ninomiya H, Ichinose J, Matsuura Y, Nakao M, Mun M, Nishio M, Okumura S, Ishikawa Y. P1.09-20 Significance of Maximal Diameter Measurement in Small-Sized Adenocarcinomas. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
21
|
Yonemizu S, Masuda K, Kurata Y, Notsu T, Higashi Y, Fukumura K, Li P, Ninomiya H, Miake J, Tsuneto M, Shirayoshi Y, Hisatome I. Inhibitory effects of class I antiarrhythmic agents on Na + and Ca 2+ currents of human iPS cell-derived cardiomyocytes. Regen Ther 2019; 10:104-111. [PMID: 30766898 PMCID: PMC6360514 DOI: 10.1016/j.reth.2018.12.002] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2018] [Revised: 12/09/2018] [Accepted: 12/19/2018] [Indexed: 11/28/2022] Open
Abstract
INTRODUCTION Human induced pluripotent stem cells (hiPSCs) harboring cardiac myosin heavy chain 6 promoter can differentiate into functional cardiomyocytes called "iCell cardiomyocytes" under blasticidin treatment condition. While iCell cardiomyocytes are expected to be used for predicting cardiotoxicity of drugs, their responses to antiarrhythmic agents remain to be elucidated. We first examined electrophysiological properties of iCell cardiomyocytes and mRNA levels of ion channels and Ca handling proteins, and then evaluated effects of class I antiarrhythmic agents on their Na+ and Ca2+ currents. METHODS iCell cardiomyocytes were cultured for 8-14 days (38-44 days after inducing their differentiation), according to the manufacturer's protocol. We determined their action potentials (APs) and sarcolemmal ionic currents using whole-cell patch clamp techniques, and also mRNA levels of ion channels and Ca handling proteins by RT-PCR. Effects of three class I antiarrhythmic agents, pirmenol, pilsicainide and mexiletine, on Na+ channel current (INa) and L-type Ca2+ channel current (ICaL) were evaluated by the whole-cell patch clamp. RESULTS iCell cardiomyocytes revealed sinoatrial node-type (18%), atrial-type (18%) and ventricular-type (64%) spontaneous APs. The maximum peak amplitudes of INa, ICaL, and rapidly-activating delayed-rectifier K+ channel current were -62.7 ± 13.7, -8.1 ± 0.7, and 3.0 ± 1.0 pA/pF, respectively. The hyperpolarization-activated cation channel and inward-rectifier K+ channel currents were observed, whereas the T-type Ca2+ channel or slowly-activating delayed-rectifier K+ channel current was not detectable. mRNAs of Nav1.5, Cav1.2, Kir2.1, HCN4, KvLQT1, hERG and SERCA2 were detected, while that of HCN1, minK or MiRP was not. The class Ia antiarrhythmic agent pirmenol and class Ic agent pilsicainide blocked INa in a concentration-dependent manner with IC50 of 0.87 ± 0.37 and 0.88 ± 0.16 μM, respectively; the class Ib agent mexiletine revealed weak INa block with a higher IC50 of 30.0 ± 3.0 μM. Pirmenol, pilsicainide and mexiletine blocked ICaL with IC50 of 2.00 ± 0.39, 7.7 ± 2.5 and 5.0 ± 0.1 μM, respectively. CONCLUSIONS In iCell cardiomyocytes, INa was blocked by the class Ia and Ic antiarrhythmic agents and ICaL was blocked by all the class I agents within the ranges of clinical concentrations, suggesting their cardiotoxicity.
Collapse
Key Words
- AP, action potential
- APA, AP amplitude
- APD, AP duration
- ET-1, Endothelin 1
- HP, holding potential
- IGF-1, insulin-like growth factor-1
- L-type Ca2+ channel current
- MDP, maximum diastolic potential
- MYH, myosin heavy chain
- MiRP, minK related protein
- Na+ channel current
- OS, overshoot potential
- SAN, sinoatrial node
- class I antiarrhythmic agents
- hiPSC, human induced pluripotent stem cell
- iCell cardiomyocytes
- minK, minimal potassium channel subunit
Collapse
Affiliation(s)
- Sayaka Yonemizu
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, 86 Nishi-cho, Yonago 683-8503, Japan
| | - Keiichiro Masuda
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, 86 Nishi-cho, Yonago 683-8503, Japan
| | - Yasutaka Kurata
- Department of Physiology II, Kanazawa Medical University, 1-1 Daigaku, Uchinada-machi, Kahoku-gun, Ishikawa 920-0293, Japan
| | - Tomomi Notsu
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, 86 Nishi-cho, Yonago 683-8503, Japan
| | - Yuhei Higashi
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, 86 Nishi-cho, Yonago 683-8503, Japan
| | - Kenta Fukumura
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, 86 Nishi-cho, Yonago 683-8503, Japan
| | - Peili Li
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, 86 Nishi-cho, Yonago 683-8503, Japan
| | - Haruaki Ninomiya
- Department of Biological Regulation, Tottori University Faculty of Medicine, Yonago 683-8503, Japan
| | - Junichiro Miake
- Department of Pharmacology, Tottori University Faculty of Medicine, Yonago 683-8503, Japan
| | - Motokazu Tsuneto
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, 86 Nishi-cho, Yonago 683-8503, Japan
| | - Yasuaki Shirayoshi
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, 86 Nishi-cho, Yonago 683-8503, Japan
| | - Ichiro Hisatome
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, 86 Nishi-cho, Yonago 683-8503, Japan
| |
Collapse
|
22
|
Taufiq F, Maharani N, Li P, Kurata Y, Ikeda N, Kuwabara M, Otani N, Miake J, Hasegawa A, Tsuneto M, Shirayoshi Y, Ninomiya H, Saitoh T, Nakai A, Yamamoto K, Hisatome I. Uric Acid-Induced Enhancements of Kv1.5 Protein Expression and Channel Activity via the Akt-HSF1-Hsp70 Pathway in HL-1 Atrial Myocytes. Circ J 2019; 83:718-726. [DOI: 10.1253/circj.cj-18-1088] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Fikri Taufiq
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| | - Nani Maharani
- Department of Pharmacology and Therapeutics, Faculty of Medicine Diponegoro University
| | - Peili Li
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| | - Yasutaka Kurata
- Department of Physiology II, Kanazawa Medical University Faculty of Medicine
| | - Nobuhito Ikeda
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| | | | - Naoyuki Otani
- Department of Clinical Pharmacology and Therapeutics, Oita University Faculty of Medicine
| | - Junichiro Miake
- Division of Cardiovascular Medicine, Department of Molecular Medicine and Therapeutics, Tottori University Faculty of Medicine
| | - Akira Hasegawa
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| | - Motokazu Tsuneto
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| | - Yasuaki Shirayoshi
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| | | | - Tatsuya Saitoh
- Division of Inflammation Biology, Institute for Enzyme Research, Tokushima University
- Laboratory of Bioresponse Regulation, Graduate School of Pharmaceutical Sciences, Osaka University
| | - Akira Nakai
- Department of Biochemistry and Molecular Biology, Yamaguchi University School of Medicine
| | - Kazuhiro Yamamoto
- Division of Cardiovascular Medicine, Department of Molecular Medicine and Therapeutics, Tottori University Faculty of Medicine
| | - Ichiro Hisatome
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| |
Collapse
|
23
|
Yamamoto K, Kurata Y, Inoue Y, Adachi M, Tsuneto M, Miake J, Ogino K, Ninomiya H, Yoshida A, Shirayoshi Y, Suyama Y, Yagi S, Nishimura M, Yamamoto K, Hisatome I. Pretreatment with an angiotensin II receptor blocker abolished ameliorating actions of adipose-derived stem cell sheets on cardiac dysfunction and remodeling after myocardial infarction. Regen Ther 2018; 9:79-88. [PMID: 30525078 PMCID: PMC6223028 DOI: 10.1016/j.reth.2018.08.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2018] [Revised: 08/10/2018] [Accepted: 08/22/2018] [Indexed: 02/07/2023] Open
Abstract
Introduction Cell sheets using myoblasts have been developed for the treatment of heart failure after myocardial infarction (MI) bridging to heart transplantation. Stem cells are supposed to be better than myoblasts as a source of cells, since they possess a potential to proliferate and differentiate into cardiomyocytes, and also have capacity to secrete angiogenic factors. Adipose-derived stem cells (ASCs) obtained from fat tissues are expected to be a new cell source for ASC sheet therapies. Administration of angiotensin II receptor blockers (ARBs) is a standard therapy for heart failure after MI. However, it is not known whether ARBs affect the cell sheet therapy. This study aimed to examine ameliorating effects of ASC sheets on heart failure and remodeling after MI, and how pretreatment with ARBs prior to the creation of MI and ASC sheet transplantation modifies the effects of ASC sheets. Methods ASCs were isolated from fat tissues of wild-type rats, and ASC sheets were engineered on temperature-responsive dishes. In in vitro studies using cultured cells, mRNA levels of vascular endothelial growth factor (VEGF) in ASCs were determined by RT-PCR in the presence of angiotensin II and/or an ARB, irbesartan, under normoxia and hypoxia; mRNA and protein levels of angiotensin II receptor type 1a (AT1aR), type 1b (AT1bR) and type 2 (AT2R) were also determined by RT-PCR and western blotting. In in vivo studies using a rat MI model, effects of transplanted ASC sheets and/or irbesartan on cardiac functions and remodeling after MI were evaluated by echocardiography, histological analysis and molecular biological techniques. Results In the in vitro studies, ASCs expressed higher levels of VEGF mRNA under hypoxia. They also expressed mRNA and protein of AT1aR but not AT1bR or AT2R. Under normoxia, angiotensin II increased the level of VEGF mRNA in ASCs, which was abolished by irbesartan. Under hypoxia, irbesartan reduced the level of VEGF mRNA in ASCs regardless of whether angiotensin II was present or not. In the in vivo studies, ASC sheets improved cardiac functions after MI, leading to decreased interstitial fibrosis and increased capillary density in border zones. These effects of ASC sheets were abolished by oral administration of irbesartan before MI and their transplantation. Conclusions ASC sheets ameliorated cardiac dysfunctions and remodeling after MI via increasing VEGF expression, which was abolished by pretreatment with irbesartan before the creation of MI and transplantation.
Collapse
Key Words
- ANP, atrial natriuretic peptide
- ARB, angiotensin receptor blocker
- ASC, adipose-derived stem cell
- AT1(2)R, angiotensin II receptor type 1(2)
- Adipose-derived stem cell sheet
- Angiotensin II
- CRT, cardiac resynchronization therapy
- EF, ejection fraction
- FGF, fibroblast growth factor
- FS, fractional shortening
- HGF, hepatocyte growth factor
- Irbesartan
- LVEDD, left ventricular end-diastolic diameter
- LVESD, left ventricular end-systolic diameter
- MI, myocardial infarction
- MSC, mesenchymal stem cell
- Myocardial infarction
- RAS, renin–angiotensin system
- VEGF
- VEGF, vascular endothelial growth factor
- vWF, von Willebrand factor
Collapse
Affiliation(s)
- Kenshiro Yamamoto
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, 86 Nishi-cho, Yonago 683-8503, Japan
| | - Yasutaka Kurata
- Department of Physiology II, Kanazawa Medical University Faculty of Medicine, 1-1 Daigaku, Uchinada-machi, Kahoku-gun, Ishikawa 920-0293, Japan
| | - Yumiko Inoue
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, 86 Nishi-cho, Yonago 683-8503, Japan
| | - Maya Adachi
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, 86 Nishi-cho, Yonago 683-8503, Japan
| | - Motokazu Tsuneto
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, 86 Nishi-cho, Yonago 683-8503, Japan
| | - Junichiro Miake
- Division of Cardiovascular Medicine, Department of Molecular Medicine and Therapeutics, Tottori University Faculty of Medicine, Yonago, Japan
| | - Kazuhide Ogino
- Department of Cardiology, Tottori Red Cross Hospital, Tottori, Japan
| | - Haruaki Ninomiya
- Department of Biological Regulation, Tottori University, Yonago, Japan
| | - Akio Yoshida
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, 86 Nishi-cho, Yonago 683-8503, Japan
| | - Yasuaki Shirayoshi
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, 86 Nishi-cho, Yonago 683-8503, Japan
| | - Yoshiko Suyama
- Department of Plastic and Reconstructive Surgery, Tottori University Faculty of Medicine, Yonago, Japan
| | - Shunjiro Yagi
- Department of Plastic and Reconstructive Surgery, Tottori University Faculty of Medicine, Yonago, Japan
| | - Motonobu Nishimura
- Department of Cardiovascular Surgery, Tottori University Faculty of Medicine, Yonago, Japan
| | - Kazuhiro Yamamoto
- Division of Cardiovascular Medicine, Department of Molecular Medicine and Therapeutics, Tottori University Faculty of Medicine, Yonago, Japan
| | - Ichiro Hisatome
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, 86 Nishi-cho, Yonago 683-8503, Japan
| |
Collapse
|
24
|
Ikeda N, Nakazawa N, Kurata Y, Yaura H, Taufiq F, Minato H, Yoshida A, Ninomiya H, Nakayama Y, Kuwabara M, Shirayoshi Y, Hisatome I. Tbx18-positive cells differentiated from murine ES cells serve as proepicardial progenitors to give rise to vascular smooth muscle cells and fibroblasts. Biomed Res 2018; 38:229-238. [PMID: 28794400 DOI: 10.2220/biomedres.38.229] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Proepicardium (PE) cells generate cardiac fibroblasts, smooth muscle cells (SMCs) and endothelial cells that form coronary arteries. T-box18 (Tbx18) is a well-known marker of PE cells and epicardium. We examined whether Tbx18-positive cells differentiated from murine embryonic stem (ES) cells serve as PE progenitors to give rise to vascular SMCs and fibroblasts. To collect Tbx18-positive cells, we established Tbx18-EGFP knock-in mouse ES cells using the CRISPR/Cas9 system. We harvested the Tbx18-EGFP-positive cells on day 8, 10 and 14 after the initiation of differentiation; Tbx18 mRNA was enriched on day 8 to 14 and Snai2 mRNA was enriched on day 8 and 10, indicating successful collection of Tbx18-positive cells. Tbx18-EGFP-positive cells expressed the PE marker WT1 on day 8 and 10. They also expressed the SMC marker Acta2 and fibroblast markers Thy1 and Fsp1 on day 8 to 14, but did not express the endothelial cell marker PECAM or the cardiac cell marker CD166 or Myh7. In conclusion, Tbx18-positive cells represent a part of PE cells in the initial phase of differentiation and subsequently include SMCs as well as fibroblasts. These results indicate that Tbx18-positive cells serve as a PE progenitor to supply a variety of cells that contribute to the formation of coronary arteries.
Collapse
Affiliation(s)
- Nobuhito Ikeda
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science
| | - Natsumi Nakazawa
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science
| | | | - Hisako Yaura
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science
| | - Fikri Taufiq
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science
| | - Hiroyuki Minato
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science
| | - Akio Yoshida
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science
| | - Haruaki Ninomiya
- Department of Biological Regulation, Tottori University Faculty of Medicine
| | - Yuji Nakayama
- Division of Functional Genomics, Research Center for Bioscience and Technology, Tottori University
| | - Masanari Kuwabara
- University of Colorado, Denver, School of Medicine, Division of Renal Diseases and Hypertension
| | - Yasuaki Shirayoshi
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science
| | - Ichiro Hisatome
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science
| |
Collapse
|
25
|
Tanno S, Yamamoto K, Kurata Y, Adachi M, Inoue Y, Otani N, Mishima M, Yamamoto Y, Kuwabara M, Ogino K, Miake J, Ninomiya H, Shirayoshi Y, Okada F, Yamamoto K, Hisatome I. Protective Effects of Topiroxostat on an Ischemia-Reperfusion Model of Rat Hearts. Circ J 2018; 82:1101-1111. [PMID: 29491325 DOI: 10.1253/circj.cj-17-1049] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND Ischemia/reperfusion (I/R) injury triggers cardiac dysfunctions via creating reactive oxygen species (ROS). Because xanthine oxidase (XO) is one of the major enzymes that generate ROS, inhibition of XO is expected to suppress ROS-induced I/R injury. However, it remains unclear whether XO inhibition really yields cardioprotection during I/R. The protective effects of the XO inhibitors, topiroxostat and allopurinol, on cardiac I/R injury were evaluated.Methods and Results:Using isolated rat hearts, ventricular functions, occurrence of arrhythmias, XO activities and thiobarbituric acid reactive substances (TBARS) productions and myocardial levels of adenine nucleotides before and after I/R, and cardiomyocyte death markers during reperfusion, were evaluated. Topiroxostat prevented left ventricular dysfunctions and facilitated recovery from arrhythmias during I/R. Allopurinol and the antioxidant, N-acetylcysteine (NAC), exhibited similar effects at higher concentrations. Topiroxostat inhibited myocardial XO activities and TBARS productions after I/R. I/R decreased myocardial levels of ATP, ADP and AMP, but increased that of xanthine. While topiroxostat, allopurinol or NAC did not change myocardial levels of ATP, ADP or AMP after I/R, all of the agents decreased the level of xanthine. They also decreased releases of CPK and LDH during reperfusion. CONCLUSIONS Topiroxostat showed protective effects against I/R injury with higher potency than allopurinol or NAC. It dramatically inhibited XO activity and TBARS production, suggesting suppression of ROS generation.
Collapse
Affiliation(s)
- Shogo Tanno
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| | - Kenshiro Yamamoto
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| | | | - Maya Adachi
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| | - Yumiko Inoue
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| | - Naoyuki Otani
- Department of Clinical Pharmacology and Therapeutics, Oita University Faculty of Medicine
| | - Mutsuo Mishima
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| | - Yasutaka Yamamoto
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| | - Masanari Kuwabara
- University of Colorado, Denver, School of Medicine, Division of Renal Diseases and Hypertension
| | - Kazuhide Ogino
- Department of Clinical Laboratory, Tottori University Hospital
| | - Junichiro Miake
- Division of Cardiovascular Medicine, Department of Molecular Medicine and Therapeutics, Faculty of Medicine, Tottori University
| | | | - Yasuaki Shirayoshi
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| | - Futoshi Okada
- Division of Pathological Biochemistry, Faculty of Medicine, Tottori University
| | - Kazuhiro Yamamoto
- Division of Cardiovascular Medicine, Department of Molecular Medicine and Therapeutics, Faculty of Medicine, Tottori University
| | - Ichiro Hisatome
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science
| |
Collapse
|
26
|
Li P, Kurata Y, Endang M, Ninomiya H, Higaki K, Taufiq F, Morikawa K, Shirayoshi Y, Horie M, Hisatome I. Restoration of mutant hERG stability by inhibition of HDAC6. J Mol Cell Cardiol 2018; 115:158-169. [PMID: 29355491 DOI: 10.1016/j.yjmcc.2018.01.009] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/02/2017] [Revised: 12/26/2017] [Accepted: 01/15/2018] [Indexed: 02/05/2023]
Abstract
The human ether-a-go-go-related gene (hERG) encodes the α subunit of a rapidly activating delayed-rectifier potassium (IKr) channel. Mutations of the hERG cause long QT syndrome type 2 (LQT2). Acetylation of lysine residues occurs in a subset of non-histone proteins and this modification is controlled by both histone acetyltransferases and deacetylases (HDACs). The aim of this study was to clarify effects of HDAC(s) on wild-type (WT) and mutant hERG proteins. WThERG and two trafficking-defective mutants (G601S and R752W) were transiently expressed in HEK293 cells, which were treated with a pan-HDAC inhibitor Trichostatin A (TSA) or an isoform-selective HDAC6 inhibitor Tubastatin A (TBA). Both TSA and TBA increased protein levels of WThERG and induced expression of mature forms of the two mutants. Immunoprecipitation showed an interaction between HDAC6 and immature forms of hERG. Coexpression of HDAC6 decreased acetylation and, reciprocally, increased ubiquitination of hERG, resulting in its decreased expression. siRNA against HDAC6, as well as TBA, exerted opposite effects. Immunochemistry revealed that HDAC6 knockdown increased expression of the WThERG and two mutants both in the endoplasmic reticulum and on the cell surface. Electrophysiology showed that HDAC6 knockdown or TBA treatment increased the hERG channel current corresponding to the rapidly activating delayed-rectifier potassium current (IKr) in HEK293 cells stably expressing the WT or mutants. Three lysine residues (K116, K495 and K757) of hERG were predicted to be acetylated. Substitution of these lysine residues with arginine eliminated HDAC6 effects. In HL-1 mouse cardiomyocytes, TBA enhanced endogenous ERG expression, increased IKr, and shortened action potential duration. These results indicate that hERG is a substrate of HDAC6. HDAC6 inhibition induced acetylation of hERG which counteracted ubiquitination leading its stabilization. HDAC6 inhibition may be a novel therapeutic option for LQT2.
Collapse
Affiliation(s)
- Peili Li
- Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University, 86-1, Nishimachi, Yonago, Tottori 683-8503, Japan.
| | - Yasutaka Kurata
- Department of Physiology II, Kanazawa Medical University, 1-1 Daigaku, Uchinada-machi, Kahoku-gun, Ishikawa 920-0293, Japan
| | - Mahati Endang
- Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University, 86-1, Nishimachi, Yonago, Tottori 683-8503, Japan
| | - Haruaki Ninomiya
- Department of Biological Regulation, Tottori University, 86-1, Nishimachi, Yonago, Tottori 683-8503, Japan
| | - Katsumi Higaki
- Research Center for Bioscience and Technology, Tottori University, 86-1, Nishimachi, Yonago, Tottori 683-8503, Japan
| | - Fikri Taufiq
- Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University, 86-1, Nishimachi, Yonago, Tottori 683-8503, Japan
| | - Kumi Morikawa
- Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University, 86-1, Nishimachi, Yonago, Tottori 683-8503, Japan
| | - Yasuaki Shirayoshi
- Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University, 86-1, Nishimachi, Yonago, Tottori 683-8503, Japan
| | - Minoru Horie
- Department of Cardiovascular Medicine, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu, Shiga 520-2192, Japan
| | - Ichiro Hisatome
- Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University, 86-1, Nishimachi, Yonago, Tottori 683-8503, Japan
| |
Collapse
|
27
|
Mun M, Sakao Y, Ichinose J, Matsuura Y, Nakao M, Nakagawa K, Ninomiya H, Motoi N, Urano Y, Okumura S, Ishikawa Y. P3.13-009 Rapid Detection of Lung Cancer by Fluorescent Imaging Using A γ-Glutamyltranspeptidase-Activatable Fluorescent Probe. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1743] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
28
|
Onohara T, Hisatome I, Kurata Y, Li P, Notsu T, Morikawa K, Otani N, Yoshida A, Iitsuka K, Kato M, Miake J, Ninomiya H, Higaki K, Shirayoshi Y, Nishihara T, Itoh T, Nakamura Y, Nishimura M. Molecular mechanisms underlying the pilsicainide-induced stabilization of hERG proteins in transfected mammalian cells. J Arrhythm 2017; 33:226-233. [PMID: 28607619 PMCID: PMC5459418 DOI: 10.1016/j.joa.2016.09.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2016] [Revised: 09/08/2016] [Accepted: 09/13/2016] [Indexed: 11/28/2022] Open
Abstract
Background Pilsicainide, classified as a relatively selective Na+ channel blocker, also has an inhibitory action on the rapidly-activating delayed-rectifier K+ current (IKr) through human ether-a-go-go-related gene (hERG) channels. We studied the effects of chronic exposure to pilsicainide on the expression of wild-type (WT) hERG proteins and WT-hERG channel currents, as well as on the expression of mutant hERG proteins, in a heterologous expression system. Methods HEK293 cells stably expressing WT or mutant hERG proteins were subjected to Western blotting, immunofluorescence microscopy and patch-clamp experiments. Results Acute exposure to pilsicainide at 0.03–10 μM influenced neither the expression of WT-hERG proteins nor WT-hERG channel currents. Chronic treatment with 0.03–10 μM pilsicainide for 48 h, however, increased the expression of WT-hERG proteins and channel currents in a concentration-dependent manner. Chronic treatment with 3 μM pilsicainide for 48 h delayed degradation of WT-hERG proteins and increased the channels expressed on the plasma membrane. A cell membrane-impermeant pilsicainide derivative did not influence the expression of WT-hERG, indicating that pilsicainide stabilized the protein inside the cell. Pilsicainide did not influence phosphorylation of Akt (protein kinase B) or expression of heat shock protein families such as HSF-1, hsp70 and hsp90. E4031, a chemical chaperone for hERG, abolished the pilsicainide effect on hERG. Chronic treatment with pilsicainide could also increase the protein expression of trafficking-defective mutant hERG, G601S and R752W. Conclusions Pilsicainide penetrates the plasma membrane, stabilizes WT-hERG proteins by acting as a chemical chaperone, and enhances WT-hERG channel currents. This mechanism could also be applicable to modulations of certain mutant-hERG proteins.
Collapse
Affiliation(s)
- Takeshi Onohara
- Division of Organ Regeneration Surgery, Tottori University Faculty of Medicine, Yonago, Japan
| | - Ichiro Hisatome
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, Nishichou 36-1, Yonago, Japan
| | - Yasutaka Kurata
- Department of Physiology II, Kanazawa Medical University, 1-1 Daigaku, Uchinada-machi, Kahoku-gun, Ishikawa, Japan
| | - Peili Li
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, Nishichou 36-1, Yonago, Japan
| | - Tomomi Notsu
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, Nishichou 36-1, Yonago, Japan
| | - Kumi Morikawa
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, Nishichou 36-1, Yonago, Japan
| | - Naoyuki Otani
- Department of Pharmacology, Dokkyo Medical College, Tochigi, Japan
| | - Akio Yoshida
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, Nishichou 36-1, Yonago, Japan
| | - Kazuhiko Iitsuka
- Division of Cardiovascular Medicine, Department of Molecular Medicine and Therapeutics, Faculty of Medicine, Tottori University, Nishichou 36-1, Yonago, Japan
| | - Masaru Kato
- Division of Cardiovascular Medicine, Department of Molecular Medicine and Therapeutics, Faculty of Medicine, Tottori University, Nishichou 36-1, Yonago, Japan
| | - Junichiro Miake
- Division of Cardiovascular Medicine, Department of Molecular Medicine and Therapeutics, Faculty of Medicine, Tottori University, Nishichou 36-1, Yonago, Japan
| | - Haruaki Ninomiya
- Department of Biological Regulation, Tottori University Faculty of Medicine, Nishichou 36-1, Yonago, Japan
| | - Katsumi Higaki
- Division of Functional Genomics, Research Center for Bioscience and Technology, Tottori University, Nishichou 36-1, Yonago, Japan
| | - Yasuaki Shirayoshi
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, Nishichou 36-1, Yonago, Japan
| | - Takashi Nishihara
- Department of Chemistry and Biotechnology, Graduate School of Engineering, Tottori University, 4-101 Koyama-minami, Tottori 680-8552, Japan.,Center for Research on Green Sustainable Chemistry, Tottori University, 4-101 Koyama-minami, Tottori 680-8552, Japan
| | - Toshiyuki Itoh
- Department of Chemistry and Biotechnology, Graduate School of Engineering, Tottori University, 4-101 Koyama-minami, Tottori 680-8552, Japan.,Center for Research on Green Sustainable Chemistry, Tottori University, 4-101 Koyama-minami, Tottori 680-8552, Japan
| | - Yoshinobu Nakamura
- Division of Organ Regeneration Surgery, Tottori University Faculty of Medicine, Yonago, Japan
| | - Motonobu Nishimura
- Division of Organ Regeneration Surgery, Tottori University Faculty of Medicine, Yonago, Japan
| |
Collapse
|
29
|
Kamada Y, Fujita T, Ishida S, Kikuchi M, Ide S, Takizuka T, Shirai H, Koide Y, Fukuda T, Hosogane N, Tsuchiya K, Hatae T, Takenaga H, Sato M, Nakamura H, Naito O, Asakura N, Kubo H, Higashijima S, Miura Y, Yoshino R, Shimizu K, Ozeki T, Hirayama T, Mori M, Sakamoto Y, Kawano Y, Isayama A, Ushigusa K, Ikeda Y, Kimura H, Fujii T, Imai T, Nagami M, Takeji S, Oikawa T, Suzuki T, Nakano T, Oyama N, Sakurai S, Konoshima S, Sugie T, Tobita K, Kondoh T, Tamai H, Neyatani Y, Sakasai A, Kusama Y, Itami K, Shimada M, Ninomiya H, Urano H. Fusion Plasma Performance and Confinement Studies on JT-60 and JT-60U. Fusion Science and Technology 2017. [DOI: 10.13182/fst02-a227] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Y. Kamada
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - T. Fujita
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - S. Ishida
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - M. Kikuchi
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - S. Ide
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - T. Takizuka
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - H. Shirai
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - Y. Koide
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - T. Fukuda
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - N. Hosogane
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - K. Tsuchiya
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - T. Hatae
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - H. Takenaga
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - M. Sato
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - H. Nakamura
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - O. Naito
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - N. Asakura
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - H. Kubo
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - S. Higashijima
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - Y. Miura
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - R. Yoshino
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - K. Shimizu
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - T. Ozeki
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - T. Hirayama
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - M. Mori
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - Y. Sakamoto
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - Y. Kawano
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - A. Isayama
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - K. Ushigusa
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - Y. Ikeda
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - H. Kimura
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - T. Fujii
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - T. Imai
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - M. Nagami
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - S. Takeji
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - T. Oikawa
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - T. Suzuki
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - T. Nakano
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - N. Oyama
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - S. Sakurai
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - S. Konoshima
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - T. Sugie
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - K. Tobita
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - T. Kondoh
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - H. Tamai
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - Y. Neyatani
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - A. Sakasai
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - Y. Kusama
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - K. Itami
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - M. Shimada
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - H. Ninomiya
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | | |
Collapse
|
30
|
Hosogane N, Ninomiya H, Matsukawa M, Ando T, Neyatani Y, Horiike H, Sakurai S, Masaki K, Yamamoto M, Kodama K, Sasajima T, Terakado T, Ohmori S, Ohmori Y, Okano J. Development and Operational Experiences of the JT-60U Tokamak and Power Supplies. Fusion Science and Technology 2017. [DOI: 10.13182/fst02-a234] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- N. Hosogane
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, 801 Mukouyama, Naka-machi Naka-gun, Ibaraki-ken 311-0193, Japan
| | - H. Ninomiya
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, 801 Mukouyama, Naka-machi Naka-gun, Ibaraki-ken 311-0193, Japan
| | - M. Matsukawa
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, 801 Mukouyama, Naka-machi Naka-gun, Ibaraki-ken 311-0193, Japan
| | - T. Ando
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, 801 Mukouyama, Naka-machi Naka-gun, Ibaraki-ken 311-0193, Japan
| | - Y. Neyatani
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, 801 Mukouyama, Naka-machi Naka-gun, Ibaraki-ken 311-0193, Japan
| | - H. Horiike
- Osaka University, Faculty of Engineering, 2-1 Yamadaoka, Suita-shi, Osaka-fu 565-0871, Japan
| | - S. Sakurai
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, 801 Mukouyama, Naka-machi Naka-gun, Ibaraki-ken 311-0193, Japan
| | - K. Masaki
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, 801 Mukouyama, Naka-machi Naka-gun, Ibaraki-ken 311-0193, Japan
| | - M. Yamamoto
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, 801 Mukouyama, Naka-machi Naka-gun, Ibaraki-ken 311-0193, Japan
| | - K. Kodama
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, 801 Mukouyama, Naka-machi Naka-gun, Ibaraki-ken 311-0193, Japan
| | - T. Sasajima
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, 801 Mukouyama, Naka-machi Naka-gun, Ibaraki-ken 311-0193, Japan
| | - T. Terakado
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, 801 Mukouyama, Naka-machi Naka-gun, Ibaraki-ken 311-0193, Japan
| | - S. Ohmori
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, 801 Mukouyama, Naka-machi Naka-gun, Ibaraki-ken 311-0193, Japan
| | - Y. Ohmori
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, 801 Mukouyama, Naka-machi Naka-gun, Ibaraki-ken 311-0193, Japan
| | - J. Okano
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment, 801 Mukouyama, Naka-machi Naka-gun, Ibaraki-ken 311-0193, Japan
| |
Collapse
|
31
|
Affiliation(s)
- A. Kitsunezaki
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Department of Fusion Plasma Research, Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - M. Shimizu
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Department of Fusion Plasma Research, Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - H. Ninomiya
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Department of Fusion Plasma Research, Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - M. Kuriyama
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Department of Fusion Plasma Research, Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | | |
Collapse
|
32
|
Nishikawa S, Tambo Y, Ninomiya H, Oguri T, Kawashima Y, Takano N, Kitazono S, Ohyanagi F, Horiike A, Yanagitani N, Ishikawa Y, Nishio M. A case treated with nivolumab after small cell lung cancer transformation of mutant EGFR non-small cell lung cancer. Ann Oncol 2016; 27:2300-2302. [PMID: 27760736 DOI: 10.1093/annonc/mdw431] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- S Nishikawa
- Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo
| | - Y Tambo
- Department of Respiratory Medicine, Kanazawa University Hospital, Kanazawa
| | - H Ninomiya
- Department of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan
| | - T Oguri
- Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo
| | - Y Kawashima
- Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo
| | - N Takano
- Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo
| | - S Kitazono
- Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo
| | - F Ohyanagi
- Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo
| | - A Horiike
- Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo
| | - N Yanagitani
- Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo
| | - Y Ishikawa
- Department of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan
| | - M Nishio
- Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo
| |
Collapse
|
33
|
Kondo T, Hisatome I, Yoshimura S, Mahati E, Notsu T, Li P, Iitsuka K, Kato M, Ogura K, Miake J, Aiba T, Shimizu W, Kurata Y, Sakata S, Nakasone N, Ninomiya H, Nakai A, Higaki K, Kawata Y, Shirayoshi Y, Yoshida A, Yamamoto K. Characterization of the novel mutant A78T-HERG from a long QT syndrome type 2 patient: Instability of the mutant protein and stabilization by heat shock factor 1. J Arrhythm 2016; 32:433-440. [PMID: 27761169 PMCID: PMC5063263 DOI: 10.1016/j.joa.2015.10.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2015] [Revised: 09/10/2015] [Accepted: 10/09/2015] [Indexed: 12/04/2022] Open
Abstract
BACKGROUND The human ether-a-go-go-related gene (HERG) encodes the α-subunit of rapidly activating delayed-rectifier potassium channels. Mutations in this gene cause long QT syndrome type 2 (LQT2). In most cases, mutations reduce the stability of the channel protein, which can be restored by heat shock (HS). METHODS We identified the novel mutant A78T-HERG in a patient with LQT2. The purpose of the current study was to characterize this mutant protein and test whether HS and heat shock factors (HSFs) could stabilize the mutant protein. A78T-HERG and wild-type HERG (WT-HERG) were expressed in HEK293 cells and analyzed by immunoblotting, immunoprecipitation, immunofluorescence, and whole-cell patch clamping. RESULTS When expressed in HEK293 cells, WT-HERG gave rise to immature and mature forms of the protein at 135 and 155 kDa, respectively. A78T-HERG gave rise only to the immature form, which was heavily ubiquitinated. The proteasome inhibitor MG132 increased the expression of immature A78T-HERG and increased both the immature and mature forms of WT-HERG. WT-HERG, but not A78T-HERG, was expressed on the plasma membrane. In whole-cell patch clamping experiments, depolarizing pulses evoked E4031-sensitive HERG channel currents in cells transfected with WT-HERG, but not in cells transfected with A78T-HERG. The A78V mutant, but not A78G mutant, remained in the immature form similarly to A78T. Maturation of the A78T-HERG protein was facilitated by HS, expression of HSF-1, or exposure to geranyl geranyl acetone. CONCLUSIONS A78T-HERG was characterized by protein instability and reduced expression on the plasma membrane. The stability of the mutant was partially restored by HSF-1, indicating that HSF-1 is a target for the treatment for LQT2 caused by the A78T mutation in HERG.
Collapse
Affiliation(s)
- Takehito Kondo
- Division of Cardiovascular Medicine, Department of Molecular Medicine and Therapeutics, Faculty of Medicine, Tottori University, Japan
| | - Ichiro Hisatome
- Division of Regenerative Medicine and Therapeutics, Tottori University Graduate School of Medical Science, Japan
| | - Shouichi Yoshimura
- Division of Regenerative Medicine and Therapeutics, Tottori University Graduate School of Medical Science, Japan
| | - Endang Mahati
- Division of Regenerative Medicine and Therapeutics, Tottori University Graduate School of Medical Science, Japan
| | - Tomomi Notsu
- Division of Regenerative Medicine and Therapeutics, Tottori University Graduate School of Medical Science, Japan
| | - Peili Li
- Division of Regenerative Medicine and Therapeutics, Tottori University Graduate School of Medical Science, Japan
| | - Kazuhiko Iitsuka
- Division of Cardiovascular Medicine, Department of Molecular Medicine and Therapeutics, Faculty of Medicine, Tottori University, Japan
| | - Masaru Kato
- Division of Cardiovascular Medicine, Department of Molecular Medicine and Therapeutics, Faculty of Medicine, Tottori University, Japan
| | - Kazuyoshi Ogura
- Division of Cardiovascular Medicine, Department of Molecular Medicine and Therapeutics, Faculty of Medicine, Tottori University, Japan
| | - Junichiro Miake
- Division of Cardiovascular Medicine, Department of Molecular Medicine and Therapeutics, Faculty of Medicine, Tottori University, Japan
| | - Takeshi Aiba
- Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Japan
| | - Wataru Shimizu
- Division of Cardiology and Regenerative Medicine, Nippon Medical School, Japan
| | - Yasutaka Kurata
- Department of Physiology II, Kanazawa Medical University, Japan
| | - Shinji Sakata
- Department of Pediatrics, Faculty of Medicine, Tottori University, Japan
| | - Naoe Nakasone
- Department of Biological Regulation, Faculty of Medicine, Tottori University, Japan
| | - Haruaki Ninomiya
- Department of Biological Regulation, Faculty of Medicine, Tottori University, Japan
| | - Akira Nakai
- Department of Biochemistry and Molecular Biology, Yamaguchi University School of Medicine, Japan
| | - Katsumi Higaki
- Division of Functional Genomics, Research Center for Bioscience and Technology, Tottori University, Japan
| | - Yasushi Kawata
- Department of Chemistry and Biotechnology, Graduate School of Engineering, Tottori University, Japan
| | - Yasuaki Shirayoshi
- Division of Regenerative Medicine and Therapeutics, Tottori University Graduate School of Medical Science, Japan
| | - Akio Yoshida
- Division of Regenerative Medicine and Therapeutics, Tottori University Graduate School of Medical Science, Japan
| | - Kazuhiro Yamamoto
- Division of Cardiovascular Medicine, Department of Molecular Medicine and Therapeutics, Faculty of Medicine, Tottori University, Japan
| |
Collapse
|
34
|
Ueno S, Hamada T, Taniguchi S, Ohtani N, Miyazaki S, Mizuta E, Ohtahara A, Ogino K, Yoshida A, Kuwabara M, Yoshida K, Ninomiya H, Kotake H, Taufiq F, Yamamoto K, Hisatome I. Effect of Antihypertensive Drugs on Uric Acid Metabolism in Patients with Hypertension: Cross-Sectional Cohort Study. Drug Res (Stuttg) 2016; 66:628-632. [PMID: 27643410 DOI: 10.1055/s-0042-113183] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Background: Hypertension is a common complication in patients with gout and/or hyperuricemia. Besides, hyperuricemia is a risk factor of gout as well as ischemic heart disease in hypertensive patients. Moreover, the risk of gout is modified by antihypertensive drugs. However, it remains unclear how antihypertensive agents affect uric acid metabolism. Purpose: In the present study, we investigated the uric acid metabolism in treated hypertensive patients to find out whether any of them would influence serum levels of uric acid. Patients and methods: 751 hypertensive patients (313 men and 438 women) under antihypertensive treatment were selected. Blood pressure (BP), serum uric acid (SUA) and serum creatinine (Scr) were measured and evaluated statistically. Results: In patients treated with diuretics, beta-blockers and/or alpha-1 blockers SUA levels were significantly higher than in patients who were not taking these drugs. Besides, the estimated glomerular filtration rate (eGFR) in patients treated with diuretics, beta-blockers and/or alpha-1 blockers was negatively correlated with SUA level. There were gender differences in the effects of beta-blockers and alpha-1 blockers. Multiple regression analysis indicated that both diuretics and beta-blockers significantly contributed to hyperuricemia in patients with medication for hypertension. Conclusion: Diuretics, beta-blockers and alpha-1 blockers reduced glomerular filtration rate and raised SUA levels. Calcium channel blockers, ACE inhibitors and angiotensin receptor blockers, including losartan, did not increase SUA levels.
Collapse
Affiliation(s)
- S Ueno
- Division of Regenerative Medicine and Therapeutics, Institute of Regenerative Medicine and Biofunction, Graduate School of Medical Sciences, Tottori University, Yonago, Japan
| | - T Hamada
- Department of Community-based Family Medicine, Tottori University Faculty of Medicine, Yonago, Japan
| | - S Taniguchi
- Department of Community-based Family Medicine, Tottori University Faculty of Medicine, Yonago, Japan
| | - N Ohtani
- Department of Pharmacology, Dokkyo Medical College, Tochigi, Japan
| | - S Miyazaki
- Division of Cardiology, Fujii Masao Memorial Hospital, Kurayosi, Japan
| | - E Mizuta
- Department of Cardiology, San-in Rosai Hospital, Yonago, Japan
| | - A Ohtahara
- Department of Cardiology, San-in Rosai Hospital, Yonago, Japan
| | - K Ogino
- Department of Clinical Laboratory, Tottori University Hospital, Yonago Japan
| | - A Yoshida
- Division of Regenerative Medicine and Therapeutics, Institute of Regenerative Medicine and Biofunction, Graduate School of Medical Sciences, Tottori University, Yonago, Japan
| | - M Kuwabara
- Department of Cardiology, Toranomon Hospital, Tokyo, Japan
| | - K Yoshida
- Center for Promoting Next-Generation Highly advanced Medicine, Tottori University Hospital, Yonago, Japan
| | - H Ninomiya
- Department of Biological Regulation, Tottori University Faculty of Medicine, Yonago, Japan
| | - H Kotake
- Kotake Cardiology Clinic, Yonago, Japan
| | - F Taufiq
- Division of Cardiology, Faculty of Medicine Diponegoro University, Semarang, Indonesia
| | - K Yamamoto
- Division of Cardiovascular Medicine, Department of Molecular Medicine and Therapeutics, Faculty of Medicine, Tottori University
| | - I Hisatome
- Division of Regenerative Medicine and Therapeutics, Institute of Regenerative Medicine and Biofunction, Graduate School of Medical Sciences, Tottori University, Yonago, Japan
| |
Collapse
|
35
|
Hamatani M, Jingami N, Uemura K, Nakasone N, Kinoshita H, Yamakado H, Ninomiya H, Takahashi R. [A case of variant biochemical phenotype of Niemann-Pick disease type C accompanying savant syndrome]. Rinsho Shinkeigaku 2016; 56:424-429. [PMID: 27181747 DOI: 10.5692/clinicalneurol.cn-000846] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
A 40-year-old man was referred to our hospital because of vertical supranuclear gaze palsy, frequent sudden loss of muscle tonus and ataxia for several years. He had a history of prolonged neonatal jaundice. He was given a diagnosis of autism in his childhood, followed by a diagnosis of schizophrenia in his teenage. He also developed a savant skill of calendar calculating. (123)I-IMP-SPECT showed decreased cerebral blood flow in the left frontotemporal lobe as often seen in savant syndrome. Although genetic analysis of NPC1 and NPC2 revealed no pathogenic mutation, filipin staining of cultured fibroblasts from his biopsied skin revealed a certain amount of intracellular cholesterol storage pattern, indicating a variant biochemical phenotype of Niemann-Pick disease type C (NPC). The diagnosis of adulthood onset NPC is difficult and challenging, especially for neurologists, because the symptoms and signs are not as clear as those in the classical childhood onset NPC and this subtype is not yet widely known. However, the diagnosis can be made by a combination of filipin staining of fibroblast and/or gene analysis. As a disease-specific therapy for NPC has been approved in Japan, the diagnosis of NPC is of significance.
Collapse
Affiliation(s)
- Mio Hamatani
- Department of Neurology, Kyoto University Graduate School of Medicine
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Ikeda N, Nakayama Y, Nakazawa N, Yoshida A, Ninomiya H, Shirayoshi Y. Prion Protein and Stage Specific Embryo Antigen 1 as Selection Markers to Enrich the Fraction of Murine Embryonic Stem Cell-Derived Cardiomyocytes. Yonago Acta Med 2016; 59:126-134. [PMID: 27493483 PMCID: PMC4973018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2016] [Accepted: 03/15/2016] [Indexed: 06/06/2023]
Abstract
BACKGROUND The prion protein (PrP) might be useful as a tool to collect cardiac progenitor cells derived from embryonic stem (ES) cells. It is also possible that PrP(+) cells include undifferentiated cells with a capacity to develop into tumors. METHODS PrP(+) cells isolated from embryoid bodies (EB) formed by mouse AB1 ES cells were examined using RT-PCR analysis and clonogeneic cell assay. To assess their potential to differentiate into cardiomyocytes, Nkx2.5(GFP/+) (hcgp7) cells, another ES cell line that carries the GFP reporter gene in the Nkx2.5 loci, were used. RESULTS PrP(+) cells isolated from EB of day 7 and 14 did not express pluripotency markers, but expressed cardiac cell markers, while PrP(+) cells isolated from EB of day 21 expressed pluripotency markers. Cultured PrP(+) cells isolated from EB of day 21 expressed pluripotency markers to form colonies, whereas those isolated from EB of day 7 and 14 did not. To exclude proliferating cells from PrP(+) cells, stage specific embryo antigen 1 (SSEA1) was employed as a second marker. PrP(+)/SSEA1(-) cells did not proliferate and expressed cardiac cell markers, while PrP(+)/SSEA1(+) did proliferate. CONCLUSION PrP(+) cells isolated from EB included undifferentiated cells in day 21. PrP(+)/SSEA1(-) cells included cardiomyoctes, suggesting PrP and SSEA1 may be useful as markers to enrich the fraction of cardiomyocytes.
Collapse
Affiliation(s)
- Nobuhito Ikeda
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, Yonago, 683-8503, Japan
| | - Yuji Nakayama
- †Division of Functional Genomics, Research Center for Bioscience and Technology, Tottori University, Yonago, 683-8503, Japan
| | - Natsumi Nakazawa
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, Yonago, 683-8503, Japan
| | - Akio Yoshida
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, Yonago, 683-8503, Japan
| | - Haruaki Ninomiya
- ‡Department of Biological Regulation, School of Health Sciences, Tottori University Faculty of Medicine, Yonago, 683-8503, Japan
| | - Yasuaki Shirayoshi
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, Yonago, 683-8503, Japan
| |
Collapse
|
37
|
Mishima M, Hamada T, Maharani N, Ikeda N, Onohara T, Notsu T, Ninomiya H, Miyazaki S, Mizuta E, Sugihara S, Kato M, Ogino K, Kuwabara M, Hirota Y, Yoshida A, Otani N, Anzai N, Hisatome I. Effects of Uric Acid on the NO Production of HUVECs and its Restoration by Urate Lowering Agents. Drug Res (Stuttg) 2016; 66:270-4. [DOI: 10.1055/s-0035-1569405] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Affiliation(s)
- M. Mishima
- Division of Regenerative Medicine and Therapeutics, Institute of Regenerative Medicine and Biofunction, Graduate School of Medical Sciences, Tottori University, Yonago, Japan
| | - T. Hamada
- Department of Regional Medicine, Tottori University Faculty of Medicine, Yonago, Japan
| | - N. Maharani
- Division of Regenerative Medicine and Therapeutics, Institute of Regenerative Medicine and Biofunction, Graduate School of Medical Sciences, Tottori University, Yonago, Japan
| | - N. Ikeda
- Division of Regenerative Medicine and Therapeutics, Institute of Regenerative Medicine and Biofunction, Graduate School of Medical Sciences, Tottori University, Yonago, Japan
| | - T. Onohara
- Division of Organ Regeneration Surgery, Tottori University Faculty of Medicine, Yonago, Japan
| | - T. Notsu
- Division of Regenerative Medicine and Therapeutics, Institute of Regenerative Medicine and Biofunction, Graduate School of Medical Sciences, Tottori University, Yonago, Japan
| | - H. Ninomiya
- Department of Biological Regulation, Tottori University Faculty of Medicine, Yonago, Japan
| | - S. Miyazaki
- Division of Cardiovascular Medicine, Fujii Masao Memorial Hospital, Kurayoshi, Japan
| | - E. Mizuta
- Department of Cardiovascular Medicine, Sanin Rosai Hospital, Yonago, Japan
| | - S. Sugihara
- Division of Cardiovascular Medicine Department of Molecular Medicine and Therapeutics, Tottori University Faculty of Medicine, Yonago, Japan
| | - M. Kato
- Division of Cardiovascular Medicine Department of Molecular Medicine and Therapeutics, Tottori University Faculty of Medicine, Yonago, Japan
| | - K. Ogino
- Department of Clinical Laboratory, Tottori University Hospital, Yonago, Japan
| | - M. Kuwabara
- Department of Cardiology, Toranomon Hospital, Tokyo, Japan
| | - Y. Hirota
- Department of Surgery, Tomimasu Surgical and Primary Care Clinic, Yonago, Japan
| | - A. Yoshida
- Division of Regenerative Medicine and Therapeutics, Institute of Regenerative Medicine and Biofunction, Graduate School of Medical Sciences, Tottori University, Yonago, Japan
| | - N. Otani
- Department of Pharmacology, Dokkyo Medical College, Tochigi, Japan
| | - N. Anzai
- Department of Pharmacology, Dokkyo Medical College, Tochigi, Japan
| | - I. Hisatome
- Division of Regenerative Medicine and Therapeutics, Institute of Regenerative Medicine and Biofunction, Graduate School of Medical Sciences, Tottori University, Yonago, Japan
| |
Collapse
|
38
|
Sogo T, Morikawa K, Kurata Y, Li P, Ichinose T, Yuasa S, Nozaki D, Miake J, Ninomiya H, Shimizu W, Fukuda K, Yamamoto K, Shirayoshi Y, Hisatome I. Electrophysiological properties of iPS cell-derived cardiomyocytes from a patient with long QT syndrome type 1 harboring the novel mutation M437V of KCNQ1. Regen Ther 2016; 4:9-17. [PMID: 31245483 PMCID: PMC6581809 DOI: 10.1016/j.reth.2015.12.001] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2015] [Revised: 12/17/2015] [Accepted: 12/24/2015] [Indexed: 02/03/2023] Open
Abstract
Introduction Long QT syndrome type 1 (LQT1) is caused by mutations in KCNQ1 coding slowly-activating delayed-rectifier K+ channels. We identified the novel missense mutation M437V of KCNQ1 in a LQT1 patient. Here, we employed iPS cell (iPSC)-derived cardiomyocytes to investigate electrophysiological properties of the mutant channel and LQT1 cardiomyocytes. Methods To generate iPSCs from the patient and a healthy subject, peripheral blood T cells were reprogrammed by Sendai virus vector encoding human OCT3/4, SOX2, KLF4, and c-MYC. Cardiomyocytes were prepared from iPSCs and human embryonic stem cells using a cytokine-based two-step differentiation method and were subjected to patch clamp experiments. Results LQT1 iPSC-derived cardiomyocytes exhibited prolongation of action potential duration (APD), which was due to a reduction of the KCNQ1-mediated current IKs; Na+, Ca2+ and other K+ channel currents were comparable. When expressed in HEK293 and COS7 cells, the mutant KCNQ1 was normally expressed in the plasma membrane but generated smaller currents than the wild type. Isoproterenol significantly prolonged APDs of LQT1 cardiomyocytes, while shortening those of healthy ones. A mathematical model for IKs-reduced human ventricular myocytes reproduced APD prolongation and generation of early afterdepolarizations (EADs) under β-adrenergic stimulation. Conclusions QT prolongation of the LQT1 patient with the mutation M437V of KCNQ1 was caused by IKs reduction, which may render the patient vulnerable to generation of EADs and arrhythmias. M437V mutation of KCNQ1 reduces channel conductance without trafficking defect. Reduced IKs of the mutant channel accounts for the prolongation of APD and QTc. Lack of medical history in this case is due to relatively small reduction in IKs. The patient is more vulnerable to generation of EAD and TdP than healthy subjects.
Collapse
Key Words
- AP(D), action potential (duration)
- C-terminus mutation
- EAD, early afterdepolarization
- EB, embryoid body
- ESC, embryonic stem cell
- Early afterdepolarization
- HP, holding potential
- ICaL, L-type Ca2+ channel current
- IK1, inward-rectifier K+ channel current
- IKr, rapidly-activating delayed-rectifier K+ channel current
- IKs, slowly-activating delayed-rectifier K+ channel current
- INa, sodium channel current
- KCNQ1
- LQT1
- LQTS, long QT syndrome
- TdP, Torsade de points
- iPS cell
- iPSC, induced pluripotent stem cell
Collapse
Affiliation(s)
- Tatsufumi Sogo
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, 86 Nishi-cho, Yonago 683-8503, Japan
| | - Kumi Morikawa
- Center for Promoting Next-Generation Highly Advanced Medicine, Tottori University Hospital, 36-1 Nishi-cho, Yonago 683-8504, Japan
| | - Yasutaka Kurata
- Department of Physiology, Kanazawa Medical University, 1-1 Daigaku, Uchinada-machi, Ishikawa 920-0293, Japan
| | - Peili Li
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, 86 Nishi-cho, Yonago 683-8503, Japan
| | - Takafumi Ichinose
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, 86 Nishi-cho, Yonago 683-8503, Japan
| | - Shinsuke Yuasa
- Department of Cardiology, Keio University School of Medicine, 35 Shinano-machi Shinjuku-ku, Tokyo 160-8582, Japan
| | - Daizou Nozaki
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, 86 Nishi-cho, Yonago 683-8503, Japan
| | - Junichiro Miake
- Division of Cardiovascular Medicine, Endocrinology and Metabolism, Department of Molecular Medicine and Therapeutics, Tottori University Faculty of Medicine, 86-1 Nishi-cho, Yonago 683-8504, Japan
| | - Haruaki Ninomiya
- Department of Biological Regulation, School of Health Science, Tottori University Faculty of Medicine, 36-1 Nishi-cho, Yonago 683-8503, Japan
| | - Wataru Shimizu
- Department of Cardiology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan
| | - Keiichi Fukuda
- Department of Cardiology, Keio University School of Medicine, 35 Shinano-machi Shinjuku-ku, Tokyo 160-8582, Japan
| | - Kazuhiro Yamamoto
- Division of Cardiovascular Medicine, Endocrinology and Metabolism, Department of Molecular Medicine and Therapeutics, Tottori University Faculty of Medicine, 86-1 Nishi-cho, Yonago 683-8504, Japan
| | - Yasuaki Shirayoshi
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, 86 Nishi-cho, Yonago 683-8503, Japan
| | - Ichiro Hisatome
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, 86 Nishi-cho, Yonago 683-8503, Japan.,Center for Promoting Next-Generation Highly Advanced Medicine, Tottori University Hospital, 36-1 Nishi-cho, Yonago 683-8504, Japan
| |
Collapse
|
39
|
Mahati E, Li P, Kurata Y, Maharani N, Ikeda N, Sakata S, Ogura K, Miake J, Aiba T, Shimizu W, Nakasone N, Ninomiya H, Higaki K, Yamamoto K, Nakai A, Shirayoshi Y, Hisatome I. M3 Muscarinic Receptor Signaling Stabilizes a Novel Mutant Human Ether-a-Go-Go-Related Gene Channel Protein via Phosphorylation of Heat Shock Factor 1 in Transfected Cells. Circ J 2016; 80:2443-2452. [PMID: 27803431 DOI: 10.1253/circj.cj-16-0712] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Endang Mahati
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science
- Department of Pharmacology and Therapeutics, Faculty of Medicine, Diponegoro University
| | - Peili Li
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science
| | | | - Nani Maharani
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science
- Department of Pharmacology and Therapeutics, Faculty of Medicine, Diponegoro University
- Center for Biomedical Research (CEBIOR), Faculty of Medicine, Diponegoro University
| | - Nobuhito Ikeda
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science
| | - Shinji Sakata
- Department of Pediatrics, Faculty of Medicine, Tottori University
| | - Kazuyoshi Ogura
- Division of Cardiovascular Medicine, Department of Molecular Medicine and Therapeutics, Faculty of Medicine, Tottori University
| | - Junichiro Miake
- Division of Cardiovascular Medicine, Department of Molecular Medicine and Therapeutics, Faculty of Medicine, Tottori University
| | - Takeshi Aiba
- Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center
| | - Wataru Shimizu
- Division of Cardiology and Regenerative Medicine, Nippon Medical School
| | - Naoe Nakasone
- Department of Biological Regulation, Faculty of Medicine, Tottori University
| | - Haruaki Ninomiya
- Department of Biological Regulation, Faculty of Medicine, Tottori University
| | - Katsumi Higaki
- Division of Functional Genomics, Research Center for Bioscience and Technology, Tottori University
| | - Kazuhiro Yamamoto
- Division of Cardiovascular Medicine, Department of Molecular Medicine and Therapeutics, Faculty of Medicine, Tottori University
| | - Akira Nakai
- Department of Biochemistry and Molecular Biology, Yamaguchi University School of Medicine
| | - Yasuaki Shirayoshi
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science
| | - Ichiro Hisatome
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science
| |
Collapse
|
40
|
Otsuki Y, Nakamura Y, Harada S, Yamamoto Y, Ogino K, Morikawa K, Ninomiya H, Miyagawa S, Sawa Y, Hisatome I, Nishimura M. Adipose stem cell sheets improved cardiac function in the rat myocardial infarction, but did not alter cardiac contractile responses to β-adrenergic stimulation. Biomed Res 2015; 36:11-9. [PMID: 25749147 DOI: 10.2220/biomedres.36.11] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Adipose stem cells (ASCs) are a source of regenerative cells available for autologous transplantation to hearts. We compared protective actions of ASC sheets on rat myocardial infarction (MI) in comparison with those of skeletal myoblast cell sheets. Their effects on infarcted hearts were evaluated by biological, histochemical as well as physiological analyses. ASC sheets secreted higher concentrations of angiogenic factors (HGF, VEGF, and bFGF; P < 0.05) under normoxic and hypoxic conditions than those of myoblast cell sheets, associated with reduction of cell apoptosis (P < 0.05). Like myoblast cell sheets, ASC sheets improved cardiac function (P < 0.05) and decreased the plasma level of ANP (P < 0.05) in MI hearts. ASC sheets restored cardiac remodeling characterized by fibrosis, cardiac hypertrophy and impaired angiogenesis (P < 0.05), which was associated with increases in angiogenic factors (P < 0.05). In isolated perfused rat hearts, ASC sheets improved both systolic and diastolic functions, which was comparable to cardiac functions of myoblast cell sheets, while both cell sheets failed to restore cardiac contractile response to either isoproterenol, pimobendan or dibutyryl cAMP. These results indicated that ASC sheets improved cardiac function and remodeling of MI hearts mediated by their paracrine action and this improvement was comparable to those by myoblast cell sheets.
Collapse
Affiliation(s)
- Yuki Otsuki
- Division of Organ Regeneration Surgery, Tottori University Faculty of Medicine
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Endo R, Bahrudin U, Notsu T, Tanno S, Onohara T, Yamaguchi S, Ikeda N, Surastri B, Nakayama Y, Ninomiya H, Shirayoshi Y, Inagaki Y, Yamamoto K, Yoshida A, Hisatome I. Carvedilol Suppresses Apoptosis and Ion Channel Remodelling of HL-1 Cardiac Myocytes Expressing E334K cMyBPC. Drug Res (Stuttg) 2015; 66:126-9. [PMID: 26479129 DOI: 10.1055/s-0035-1555772] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
BACKGROUND Besides its antiarrhythmic action, carvedilol has an activity to suppress cardiac tissue damage. However, it is unknown whether it has any effect on cellular apoptosis and ion channel remodelling. PURPOSE To know whether carvedilol has any effect on apoptosis and ion channel remodeling of HL-1 cells expressing E334K MyBPC, and comparing it with bisoprolol. METHOD We examined effects of carvedilol and bisoprolol on the levels of pro- and anti-apoptotic proteins and ion channels as well as apoptosis of HL-1 cells transfected with E334K MyBPC using Western blot and flow cytometry. RESULTS Carvedilol decreased the protein levels of p53, Bax and cytochrome c and increased that of Bcl-2 in HL-1 cells expressing E334K MyBPC. Bisoprolol failed to affect the protein levels. Both carvedilol and bisoprolol increased the protein levels of Cav1.2 but not that of Nav1.5. Carvedilol was stronger than bisoprolol at decreasing the number of annexin-V positive cells in HL-1 cells expressing E334K MyBPC. CONCLUSION Carvedilol suppressed apoptosis of HL-1 cells expressing E334K MyBPC through modification of pro- and anti-apoptotic proteins, whose was associated with an increase of Cav 1.2 protein expression.
Collapse
Affiliation(s)
- R Endo
- Department of Anesthesiology, Tottori University Faculty of Medicine, Yonago, Japan
| | - U Bahrudin
- Division of Regenerative Medicine and Therapeutics, Tottori University Graduate School of Medical Science, Yonago, Japan
| | - T Notsu
- Division of Regenerative Medicine and Therapeutics, Tottori University Graduate School of Medical Science, Yonago, Japan
| | - S Tanno
- Division of Regenerative Medicine and Therapeutics, Tottori University Graduate School of Medical Science, Yonago, Japan
| | - T Onohara
- Division of Organ Regeneration Surgery, Tottori University Faculty of Medicine, Yonago, Japan
| | - S Yamaguchi
- Division of Regenerative Medicine and Therapeutics, Tottori University Graduate School of Medical Science, Yonago, Japan
| | - N Ikeda
- Division of Regenerative Medicine and Therapeutics, Tottori University Graduate School of Medical Science, Yonago, Japan
| | - B Surastri
- Department of Pharmacology, Diponegoro University Faculty of Medicine, Semarang, Indonesia
| | - Y Nakayama
- Division of Functional Genomics, Research Center for Bioscience and Technology, Tottori University, Yonago, Japan
| | - H Ninomiya
- Department of Biological Regulation, Tottori University Faculty of Medicine, Yonago, Japan
| | - Y Shirayoshi
- Division of Regenerative Medicine and Therapeutics, Tottori University Graduate School of Medical Science, Yonago, Japan
| | - Y Inagaki
- Department of Anesthesiology, Tottori University Faculty of Medicine, Yonago, Japan
| | - K Yamamoto
- Department of Multidisciplinary Internal Medicine, School of Medicine, Tottori University, Yonago, Japan
| | - A Yoshida
- Division of Regenerative Medicine and Therapeutics, Tottori University Graduate School of Medical Science, Yonago, Japan
| | - I Hisatome
- Division of Regenerative Medicine and Therapeutics, Tottori University Graduate School of Medical Science, Yonago, Japan
| |
Collapse
|
42
|
Maharani N, Ting YK, Cheng J, Hasegawa A, Kurata Y, Li P, Nakayama Y, Ninomiya H, Ikeda N, Morikawa K, Yamamoto K, Makita N, Yamashita T, Shirayoshi Y, Hisatome I. Molecular Mechanisms Underlying Urate-Induced Enhancement of Kv1.5 Channel Expression in HL-1 Atrial Myocytes. Circ J 2015; 79:2659-68. [PMID: 26477273 DOI: 10.1253/circj.cj-15-0416] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND Hyperuricemia induces endothelial dysfunction, oxidative stress and inflammation, increasing cardiovascular morbidities. It also raises the incidence of atrial fibrillation; however, underlying mechanisms are unknown. METHODS AND RESULTS The effects of urate on expression of Kv1.5 in cultured mouse atrial myocytes (HL-1 cells) using reverse transcriptase-PCR, immunoblots, flow cytometry and patch-clamp experiments were studied. Treatment with urate at 7 mg/dl for 24 h increased the Kv1.5 protein level, enhanced ultra-rapid delayed-rectifier K(+)channel currents and shortened action potential duration in HL-1 cells. HL-1 cells expressed the influx uric acid transporter (UAT), URATv1, and the efflux UATs, ABCG2 and MRP4. An inhibitor against URATv1, benzbromarone, abolished the urate effects, whereas an inhibitor against ABCG2, KO143, augmented them. Flow cytometry showed that urate induced an increase in reactive oxygen species, which was abolished by the antioxidant, N-acetylcysteine (NAC), and the NADPH-oxidase inhibitor, apocynin. Both NAC and apocynin abolished the enhancing effects of urate on Kv1.5 expression. A urate-induced increase in the Kv1.5 proteins was accompanied by phosphorylation of extracellular signal-regulated kinase (ERK), and was abolished by an ERK inhibitor, PD98059. NAC abolished phosphorylation of ERK by urate. CONCLUSIONS Intracellular urate taken up by UATs enhanced Kv1.5 protein expression and function in HL-1 atrial myocytes, which could be attributable to ERK phosphorylation and oxidative stress derived from nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase.
Collapse
Affiliation(s)
- Nani Maharani
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Li P, Kurata Y, Maharani N, Mahati E, Higaki K, Hasegawa A, Shirayoshi Y, Yoshida A, Kondo T, Kurozawa Y, Yamamoto K, Ninomiya H, Hisatome I. E3 ligase CHIP and Hsc70 regulate Kv1.5 protein expression and function in mammalian cells. J Mol Cell Cardiol 2015; 86:138-46. [PMID: 26232501 DOI: 10.1016/j.yjmcc.2015.07.018] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/27/2014] [Revised: 07/05/2015] [Accepted: 07/23/2015] [Indexed: 01/29/2023]
Abstract
Kv1.5 confers ultra-rapid delayed-rectifier potassium channel current (IKur) which contributes to repolarization of the atrial action potential. Kv1.5 proteins, degraded via the ubiquitin-proteasome pathway, decreased in some atrial fibrillation patients. Carboxyl-terminus heat shock cognate 70-interacting protein (CHIP), an E3 ubiquitin ligase, is known to ubiquitinate short-lived proteins. Here, we investigated the roles of CHIP in Kv1.5 degradation to provide insights into the mechanisms of Kv1.5 decreases and treatments targeting Kv1.5 for atrial fibrillation. Coexpression of CHIP with Kv1.5 in HEK293 cells increased Kv1.5 protein ubiquitination and decreased the protein level. Immunofluorescence revealed decreases of Kv1.5 proteins in the endoplasmic reticulum and on the cell membrane. A siRNA against CHIP suppressed Kv1.5 protein ubiquitination and increased its protein level. CHIP mutants, lacking either the N-terminal tetratricopeptide region domain or the C-terminal U-box domain, failed to exert these effects on Kv1.5 proteins. Immunoprecipitation showed that CHIP formed complexes with Kv1.5 proteins and heat shock cognate protein 70 (Hsc70). Effects of Hsc70 on Kv1.5 were similar to CHIP by altering interaction of CHIP with Kv1.5 protein. Coexpression of CHIP and Hsc70 with Kv1.5 additionally enhanced Kv1.5 ubiquitination. Kv1.5 currents were decreased by overexpression of CHIP or Hsc70 but were increased by knockdown of CHIP or Hsc70 in HEK 293 cells stably expressing Kv1.5. These effects of CHIP and Hsc70 were also observed on endogenous Kv1.5 in HL-1 mouse cardiomyocytes, decreasing IKur and prolonging action potential duration. These results indicate that CHIP decreases the Kv1.5 protein level and functional channel by facilitating its degradation in concert with chaperone Hsc70.
Collapse
Affiliation(s)
- Peili Li
- Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University, Graduate School of Medical Science, Nishimachi 36, Yonago, Japan.
| | - Yasutaka Kurata
- Department of Physiology, Kanazawa Medical University, Ishikawa 920-0293, Japan
| | - Nani Maharani
- Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University, Graduate School of Medical Science, Nishimachi 36, Yonago, Japan
| | - Endang Mahati
- Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University, Graduate School of Medical Science, Nishimachi 36, Yonago, Japan
| | - Katsumi Higaki
- Department of Human Genome Science, Tottori University, Faculty of Medicine, Nishichou 86, Yonago 683, Japan
| | - Akira Hasegawa
- Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University, Graduate School of Medical Science, Nishimachi 36, Yonago, Japan
| | - Yasuaki Shirayoshi
- Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University, Graduate School of Medical Science, Nishimachi 36, Yonago, Japan
| | - Akio Yoshida
- Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University, Graduate School of Medical Science, Nishimachi 36, Yonago, Japan
| | - Tatehito Kondo
- Department of Cardiovascular Medicine, Tottori University, Faculty of Medicine, Nishichou 86, Yonago 683, Japan
| | - Youichi Kurozawa
- Division of Health Administration and Promotion, Tottori University, Faculty of Medicine, Nishichou 86, Yonago 683, Japan
| | - Kazuhiro Yamamoto
- Department of Cardiovascular Medicine, Tottori University, Faculty of Medicine, Nishichou 86, Yonago 683, Japan
| | - Haruaki Ninomiya
- Department of Biological Regulation, Tottori University, Faculty of Medicine, Nishichou 86, Yonago 683, Japan
| | - Ichiro Hisatome
- Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University, Graduate School of Medical Science, Nishimachi 36, Yonago, Japan
| |
Collapse
|
44
|
Sugihara S, Hisatome I, Kuwabara M, Niwa K, Maharani N, Kato M, Ogino K, Hamada T, Ninomiya H, Higashi Y, Ichida K, Yamamoto K. Depletion of Uric Acid Due to SLC22A12 (URAT1) Loss-of-Function Mutation Causes Endothelial Dysfunction in Hypouricemia. Circ J 2015; 79:1125-32. [PMID: 25739858 DOI: 10.1253/circj.cj-14-1267] [Citation(s) in RCA: 78] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND Uric acid (UA) serves as an antioxidant in vascular endothelial cells. UA transporter 1 (URAT1) encoded by SLC22A12 is expressed in the kidney and vessels and its loss of function causes hypouricemia. The purpose of this study was to examine whether there is any endothelial dysfunction in patients with hypouricemia. METHODS AND RESULTS Twenty-six patients with hypouricemia (<2.5 mg/dl) and 13 healthy control subjects were enrolled. Endothelial function was evaluated using flow-mediated dilation (FMD). mRNA of UA transporters expressed in cultured human umbilical endothelial cells (HUVEC) was detected on RT-PCR. There was a positive correlation between FMD and serum UA in the hypouricemia group. URAT1 loss-of-function mutations were found in the genome of 21 of 26 patients with hypouricemia, and not in the other 5. In the hypouricemia groups, serum UA in homozygous and compound heterozygous patients was significantly lower than in other groups, suggesting that severity of URAT1 dysfunction may influence the severity of hypouricemia. Thirteen of 16 hypouricemia subjects with homozygous and compound heterozygote mutations had SUA <0.8 mg/dl and their FMD was lower than in other groups. HUVEC do not express mRNA of URAT1, suggesting the null role of URAT1 in endothelial function. CONCLUSIONS Depletion of UA due to SLC22A12/URAT1 loss-of-function mutations causes endothelial dysfunction in hypouricemia patients.
Collapse
Affiliation(s)
- Shinobu Sugihara
- Division of Cardiovascular Medicine, Department of Molecular Medicine and Therapeutics Faculty of Medicine, Tottori University
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Yu Y, Mena-Barragán T, Higaki K, Johnson JL, Drury JE, Lieberman RL, Nakasone N, Ninomiya H, Tsukimura T, Sakuraba H, Suzuki Y, Nanba E, Mellet CO, García Fernández JM, Ohno K. Molecular basis of 1-deoxygalactonojirimycin arylthiourea binding to human α-galactosidase a: pharmacological chaperoning efficacy on Fabry disease mutants. ACS Chem Biol 2014; 9:1460-9. [PMID: 24783948 DOI: 10.1021/cb500143h] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Fabry disease (FD) is an X-linked lysosomal storage disorder caused by mutations in the GLA gene often leading to missense α-galactosidase A (α-Gal A) variants that undergo premature endoplasmic reticulum-associated degradation due to folding defects. We have synthesized and characterized a new family of neutral amphiphilic pharmacological chaperones, namely 1-deoxygalactonojirimycin-arylthioureas (DGJ-ArTs), capable of stabilizing α-Gal A and restoring trafficking. Binding to the enzyme is reinforced by a strong hydrogen bond involving the aryl-N'H thiourea proton and the catalytic aspartic acid acid D231 of α-Gal A, as confirmed by a 2.55 Å resolution cocrystal structure. Selected candidates enhanced α-Gal A activity and ameliorate globotriaosylceramide (Gb3) accumulation and autophagy impairments in FD cell cultures. Moreover, they acted synergistically with the proteostasis regulator 4-phenylbutyric acid, appearing to be promising leads as pharmacological chaperones for FD.
Collapse
Affiliation(s)
- Yi Yu
- Division
of Functional Genomics, Research Center for Bioscience and Technology, Tottori University, Yonago 683-8503, Japan
- Division
of Child Neurology, Institute of Neurological Sciences, Tottori University Faculty of Medicine, Yonago 683-8504, Japan
| | - Teresa Mena-Barragán
- Departamento
de Química Orgánica, Facultad de Química, Universidad de Sevilla, Sevilla 41012, Spain
| | - Katsumi Higaki
- Division
of Functional Genomics, Research Center for Bioscience and Technology, Tottori University, Yonago 683-8503, Japan
| | - Jennifer L. Johnson
- School of Chemistry & Biochemistry, Georgia Institute of Technology, Atlanta 30332-0400, Georgia United States
| | - Jason E. Drury
- School of Chemistry & Biochemistry, Georgia Institute of Technology, Atlanta 30332-0400, Georgia United States
| | - Raquel L. Lieberman
- School of Chemistry & Biochemistry, Georgia Institute of Technology, Atlanta 30332-0400, Georgia United States
| | - Naoe Nakasone
- Department
of Biomedical Regulation, School of Health Science, Tottori University Faculty of Medicine, Yonago 683-8503, Japan
| | - Haruaki Ninomiya
- Department
of Biomedical Regulation, School of Health Science, Tottori University Faculty of Medicine, Yonago 683-8503, Japan
| | - Takahiro Tsukimura
- Department
of Functional Bioanalysis, Meiji Pharmaceutical University, Tokyo 204-8588, Japan
| | - Hitoshi Sakuraba
- Department
of Clinical Genetics, Meiji Pharmaceutical University, Tokyo 204-8588, Japan
| | - Yoshiyuki Suzuki
- Tokyo Metropolitan Institute of Medical Science, Tokyo 156-0057, Japan
| | - Eiji Nanba
- Division
of Functional Genomics, Research Center for Bioscience and Technology, Tottori University, Yonago 683-8503, Japan
| | - Carmen Ortiz Mellet
- Departamento
de Química Orgánica, Facultad de Química, Universidad de Sevilla, Sevilla 41012, Spain
| | | | - Kousaku Ohno
- Division
of Child Neurology, Institute of Neurological Sciences, Tottori University Faculty of Medicine, Yonago 683-8504, Japan
| |
Collapse
|
46
|
Nakasone N, Nakamura YS, Higaki K, Oumi N, Ohno K, Ninomiya H. Endoplasmic reticulum-associated degradation of Niemann-Pick C1: evidence for the role of heat shock proteins and identification of lysine residues that accept ubiquitin. J Biol Chem 2014; 289:19714-25. [PMID: 24891511 DOI: 10.1074/jbc.m114.549915] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Most cases with Niemann-Pick disease type C carry mutations in NPC1. Some of the mutations, including the most frequent I1061T, give rise to unstable proteins selected for endoplasmic reticulum-associated degradation. The purpose of the current study was to shed mechanistic insights into the degradation process. A proteasome inhibitor MG132 prolonged the life span of the wild-type NPC1 expressed in COS cells. The expressed protein associated with multiple chaperones including heat shock protein 90 (Hsp90), Hsp70, heat shock cognate protein 70 (Hsc70), and calnexin. Accordingly, expression of an E3 ligase CHIP (carboxyl terminus of Hsp70-interacting protein) enhanced MG132-induced accumulation of ubiquitylated NPC1. Co-expression and RNAi knockdown experiments in HEK cells indicated that Hsp70/Hsp90 stabilized NPC1, whereas Hsc70 destabilized it. In human fibroblasts carrying the I1061T mutation, adenovirus-mediated expression of Hsp70 or treatment with an HSP-inducer geranylgeranylacetone (GGA) increased the level of the mutant protein. In GGA-treated cells, the rescued protein was localized in the late endosome and ameliorated cholesterol accumulation. MALDI-TOF mass spectrometry revealed three lysine residues at amino acids 318, 792, and 1180 as potential ubiquitin-conjugation sites. Substitutions of the three residues with alanine yielded a mutant protein with a steady-state level more than three times higher than that of the wild-type. Introduction of the same substitutions to the I1061T mutant resulted in an increase in its protein level and functional restoration. These findings indicated the role of HSPs in quality control of NPC1 and revealed the role of three lysine residues as ubiquitin-conjugation sites.
Collapse
Affiliation(s)
| | - Yuko S Nakamura
- Applied Biotechnology, Tottori Institute of Industrial Technology, Yonago 684-0041
| | - Katsumi Higaki
- the Division of Functional Genomics, Research Center for Bioscience and Technology, Tottori University, Yonago 683-8503, and
| | - Nao Oumi
- the Tottori University Hospital Cancer Center, Yonago 683-8504, Japan
| | - Kousaku Ohno
- Child Neurology, Tottori University Faculty of Medicine, Yonago 683-8503
| | | |
Collapse
|
47
|
Miyazaki S, Hamada T, Hirata S, Ohtahara A, Mizuta E, Yamamoto Y, Kuwabara M, Nosaka Y, Igawa O, Ogino K, Kato M, Yoshida A, Ninomiya H, Cheng J, Moriwaki Y, Yamamoto K, Hisatome I. Effects of azelnidipine on uric acid metabolism in patients with essential hypertension. Clin Exp Hypertens 2014; 36:447-53. [PMID: 24433018 DOI: 10.3109/10641963.2013.846359] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
PURPOSE To examine effects of a long-acting calcium channel blocker (CCB) azelnidipine on uric acid metabolism in hypertensive patients. METHODS Azelnidipine was administered to 72 patients at a daily dose of 8 mg or 16 mg. In 22 cases out of the 72 patients, a different CCB was switched to azelnidipine. Blood pressure was measured and biochemical parameters of blood and urine were evaluated before and 2-3 months after the administration. RESULTS Azelnidipine significantly decreased both systolic and diastolic blood pressure and the heart rate. It decreased both serum urate levels and the urinary uric acid to creatinine ratio (Uur/Ucr), but did not affect the uric acid clearance to creatinine clearance ratio (Cur/Ccr). Azelnidipine decreased both Uur/Ucr and Cur/Ccr in patients with Uur/Ucr ≥ 0.5 or ≥ 0.34, although it did not change these clearance parameters in patients with Uur/Ucr <0.5 or <0.34. Azelnidipine decreased the serum urate levels and Uur/Ucr in hyperuricemic patients with uric acid levels ≥ 7.0 mg/dL in males and ≥ 6.0 mg/dL in females. It did not change these parameters in normouricemic patients with serum urate levels <7.0 mg/dL in males and <6.0 mg/dL in females. Azelnidipine decreased Uur/Ucr and Cur/Ccr in hyperuricemic patients with normal or over excretion of uric acid, although it did not change these clearance parameters in hyperuricemic patients with uric acid hypoexcretion. CONCLUSIONS Azelnidipine decreased the serum urate acid levels and Uur/Ucr, and this response was most prominent in hyperuricemic patients or patients with normal and over excretion of uric acid.
Collapse
|
48
|
Nindita Y, Hamada T, Bahrudin U, Hosoyamada M, Ichida K, Iwai C, Urashima S, Kuwabara M, Utami S, Mizuta E, Yamada K, Igawa O, Shigemasa C, Ninomiya H, Tsuchihashi T, Hisatome I. Effect of losartan and benzbromarone on the level of human urate transporter 1 mRNA. Drug Res (Stuttg) 2014. [DOI: 10.1055/s-0033-1363730] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- Yora Nindita
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction
| | - Toshihiro Hamada
- Department of Cardiovascular Medicine, Tottori University Faculty of Medicine Yonago
| | - Udin Bahrudin
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction
| | | | - Kimiyoshi Ichida
- Department of Pathophysiology, Tokyo University of Pharmacy and Life Science
| | - Chisato Iwai
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction
| | - Sunao Urashima
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction
| | - Masanari Kuwabara
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction
| | - Sulistiyati Utami
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction
| | - Einosuke Mizuta
- Department of Cardiovascular Medicine, Tottori University Faculty of Medicine Yonago
| | - Kensaku Yamada
- Department of Cardiovascular Medicine, Tottori University Faculty of Medicine Yonago
| | - Osamu Igawa
- Department of Cardiovascular Medicine, Tottori University Faculty of Medicine Yonago
| | - Chiaki Shigemasa
- Department of Cardiovascular Medicine, Tottori University Faculty of Medicine Yonago
| | - Haruaki Ninomiya
- Department of Biological Regulation, Tottori University Faculty of Medicine Yonago
| | - Takuya Tsuchihashi
- Division of Hypertension, Clinical Research Center, National Kyushu Medical Center
| | - Ichiro Hisatome
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction
| |
Collapse
|
49
|
Endo R, Notsu T, Mishima M, Morikawa K, Li P, Ikeda N, Ninomiya H, Shirayoshi Y, Hisatome I. Bepridil Suppresses Apoptosis in HL-1 Cardiac Atrial Myocytes Expressing Mutant E334K cMyBPC. Yonago Acta Med 2013; 56:93-95. [PMID: 24574578 PMCID: PMC3935176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2013] [Accepted: 11/01/2013] [Indexed: 06/03/2023]
Abstract
Besides its antiarrhythmic effect on atrial fibrillation, bepridil protects tissue, yet its effect on apoptosis has never been fully tested. We examine the effect of bepridil on apoptosis of HL-1 cells expressing E334K myosin-binding protein C (MyBPC), a model cell of apoptosis. Bepridil was compared with amiodarone, and its effects on the expression of pro- and anti-apoptotic protein and apoptosis of HL-1 cells expressing mutant E334K MyBPC-green fluorescent protein (GFP) was analyzed using Western blot and a flow cytometer. Bepridil decreased the protein levels of both Bax and cytochrome c of cells expressing E334K MyBPC-GFP with no changes in p53 and Bcl-2, while amiodarone decreased cytochrome c but did not influence Bax except in its highest concentration. It also decreased the number of Annexin-V positive cells of HL-1 cells expressing E334K MyBPC-GFP, and decreased apoptosis of HL-1 cells expressing E334K MyBPC-GFP.
Collapse
Affiliation(s)
- Ryo Endo
- Division of Anesthesiology and Critical Care Medicine, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8504, Japan
| | - Tomomi Notsu
- †Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University, Yonago 683-8503, Japan
| | - Mutsuo Mishima
- †Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University, Yonago 683-8503, Japan
| | - Kumi Morikawa
- †Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University, Yonago 683-8503, Japan
| | - Peili Li
- †Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University, Yonago 683-8503, Japan
| | - Nobuhito Ikeda
- †Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University, Yonago 683-8503, Japan
| | - Haruaki Ninomiya
- ‡Department of Biological Regulation, School of Health Science, Tottori University Faculty of Medicine, Yonago 683-8503, Japan
| | - Yasuaki Shirayoshi
- †Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University, Yonago 683-8503, Japan
| | - Ichiro Hisatome
- †Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University, Yonago 683-8503, Japan
| |
Collapse
|
50
|
Iwai C, Li P, Kurata Y, Hoshikawa Y, Morikawa K, Maharani N, Higaki K, Sasano T, Notsu T, Ishido Y, Miake J, Yamamoto Y, Shirayoshi Y, Ninomiya H, Nakai A, Murata S, Yoshida A, Yamamoto K, Hiraoka M, Hisatome I. Hsp90 prevents interaction between CHIP and HERG proteins to facilitate maturation of wild-type and mutant HERG proteins. Cardiovasc Res 2013; 100:520-8. [PMID: 23963841 DOI: 10.1093/cvr/cvt200] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
AIMS We examined the role of Hsp90 in expression and maturation of wild-type (WT) and mutant ether-a-go-go related gene (HERG) proteins by using Hsp90 inhibitors, geldanamycin (GA) and radicicol, and Hsp90 overexpression. METHODS AND RESULTS The proteins were expressed in HEK293 cells or collected from HL-1 mouse cardiomyocytes, and analysed by western blotting, immunoprecipitation, immunofluorescence, and whole-cell patch-clamp techniques. GA and radicicol suppressed maturation of HERG-FLAG proteins and increased their immature forms. Co-expression of Hsp90 counteracted the effects of Hsp90 inhibitors and suppressed ubiquitination of HERG proteins. Overexpressed Hsp90 also inhibited the binding of endogenous C-terminus of Hsp70-interacting protein (CHIP) to HERG-FLAG proteins. Hsp90-induced increase of functional HERG proteins was verified by their increased expression on the cell surface and enhanced HERG channel currents. CHIP overexpression decreased both mature and immature forms of HERG-FLAG proteins in cells treated with GA. Hsp90 facilitated maturation of endogenous ERG proteins, whereas CHIP decreased both forms of ERG proteins in HL-1 cells. Mutant HERG proteins harbouring disease-causing missense mutations were mainly in the immature form and had a higher binding capacity to CHIP than the WT; Hsp90 overexpression suppressed this association. Overexpressed Hsp90 increased the mature form of HERG(1122fs/147) proteins, reduced its ubiquitinated form, increased its immunoreactivity in the endoplasmic reticulum and on the plasma membrane, and increased the mutant-mediated membrane current. CHIP overexpression decreased the immature form of HERG(1122fs/147) proteins. CONCLUSION Enhancement of HERG protein expression through Hsp90 inhibition of CHIP binding might be a novel therapeutic strategy for long QT syndrome 2 caused by trafficking abnormalities of HERG proteins.
Collapse
Affiliation(s)
- Chisato Iwai
- Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science. Nishichou 86, Yonago 683, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|